

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [editorial.bmjopen@bmj.com](mailto:editorial.bmjopen@bmj.com)

# BMJ Open

## The Effectiveness of Mindfulness-Based Interventions in Patients with COPD: A systematic review and meta-analysis protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-026061
Article Type:	Protocol
Date Submitted by the Author:	15-Aug-2018
Complete List of Authors:	tian, lingyun; Central South University, Xiangya Nursing School; Anhui University of Chinese Medicine, School of Nursing zhang, ying; Central South University, Department of infection control , Xiangya hospital li, li; Central South University, Department of nursing, Xiangya hospital wu, ying; Central South University, Department of burn, Xiangya hospital Li, Ying-lan; Central South University, Department of nursing, Xiangya hospital
Keywords:	MEDICAL EDUCATION & TRAINING, MENTAL HEALTH, Chronic airways disease < THORACIC MEDICINE

SCHOLARONE™  
Manuscripts

1  
2  
3 **The Effectiveness of Mindfulness-Based Interventions in Patients with COPD: A**  
4 **systematic review and meta-analysis protocol**  
5

6  
7 Lingyun Tian<sup>1, 2</sup>, Ying Zhang<sup>3</sup>, Li Li<sup>4</sup>, Ying Wu<sup>5</sup>, Yinglan Li<sup>4</sup>  
8

9 1 Xiangya Nursing School, Central South University, Changsha, China  
10

11 2 School of Nursing, Anhui University of Chinese Medicine, Hefei, China  
12

13 3 Department of infection control , Xiangya hospital, Central South University,  
14 Changsha, China  
15

16 4 Department of nursing, Xiangya hospital, Central South University, Changsha,  
17 China  
18

19 5 Department of burn, Xiangya hospital, Central South University, Changsha, China  
20  
21  
22

23  
24 **Email:**

25  
26 Lingyun Tian: [tianlingyun@csu.edu.cn](mailto:tianlingyun@csu.edu.cn)

27  
28 Ying Zhang: [350208667@qq.com](mailto:350208667@qq.com)

29  
30 Li Li: [468053702@qq.com](mailto:468053702@qq.com)

31  
32 Ying Wu: [wuying2341@126.com](mailto:wuying2341@126.com)

33  
34 Yinglan Li: [yuyan0202@sina.com](mailto:yuyan0202@sina.com)

35 **correspondence to professor** Yinglan Li.  
36

37 **Address:** 87 Xiang Ya Road Changsha 410008 Hunan, China  
38

39 **Word count:** 3752  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Abstract

**Introduction** Chronic obstructive pulmonary disease (COPD) is a common chronic respiratory disease, accompanied by the main symptoms of coughing, shortness of breath, and dyspnea. It has adverse effects on the physical health, mental well-being, and quality of life of the patients. The mindfulness-based interventions(MBIs) aim to raise awareness of present moment experience, help us to enjoy our daily experiences and manage our lives better. At present, there were some studies to explore the intervention effect of MBIs on COPD patients, but the results were not consistent. It is necessary to systematically review and provide the available evidence about the efficacy of MBIs on patients with COPD.

**Methods and analysis** Randomized controlled trials(RCTs) that evaluated the effect of MBIs for the treatment of COPD patients ,which with acute exacerbations within the 4 weeks before studies would be excluded, will be searched in the databases of PubMed, Embase, Web of Science, the Cochrane Library, and China National Knowledge Infrastructure(CNKI). Primary outcome measures will include exercise capacity, dyspnea, fatigue, scores of depression, scores of anxiety. Secondary outcome measures will include quality of life, scores of mindfulness and lung function. Two researchers will independently conduct data extraction, and the bias risk in each included study will be evaluated based on the Cochrane Handbook of Systematic Reviews of Interventions by two researchers. All analyses will be conducted by Review Manager 5.3. and Stata12.0.

**Ethics and dissemination** This systematic review does not need to be examined and agreed by the ethics committee. And the results of the study will be exchanged as a conference paper or published in a journal.

**PROSPERO registration number** CRD42018102323

### strengths and limitations of this study

This study will be the first time to systematically review the efficacy of MBIs in COPD patients comprehensively.

The results of this study may offer some help to patients, clinical medical workers

1  
2  
3 and health policy makers concerning the application of MBIs in the treatment of  
4 COPD.  
5

6 Although detailed retrieval strategies have been formulated in our study, unpublished  
7 trials may not be included, which may lead to publication bias.  
8  
9

## 10 11 12 **INTRODUCTION** 13

14 Chronic obstructive pulmonary disease (COPD) is a common and frequently  
15 occurring disease that endangers human health. The mortality of COPD is high, and  
16 the quality of patients' life is poor, which brings heavy financial burden to patients  
17 and their families and society.<sup>1</sup> COPD is characterized by persistent and progressive  
18 airflow limitation, accompanied by an increase in chronic inflammatory responses  
19 caused by harmful particles or gases in the airway and lungs, and acute exacerbation  
20 and comorbidities affect the overall severity of the disease.<sup>2</sup>  
21  
22  
23  
24  
25  
26

27 The study have pointed out that, by 2020, COPD may be leaping from the current  
28 fourth to the third place in the cause of death all around the world, and will be ranked  
29 fifth in the global economic burden.<sup>3</sup> Studies have shown that the incidence of COPD  
30 worldwide is about 10%.<sup>4</sup> An epidemiological survey of COPD in China has shown  
31 that the prevalence of COPD is 8.2% for people older than 40 years old, the number  
32 of deaths caused by COPD is more than 1 million a year, and about 5~10 million  
33 people were disabled.<sup>5</sup> In rural areas, the mortality rate of respiratory diseases ranked  
34 first among all kinds of causes of death in China.<sup>6</sup>  
35  
36  
37  
38  
39  
40  
41

42 Numerous studies have shown that COPD is a chronic airway disease  
43 with a characteristic of persistent airflow limitation, as well as a systematic disease  
44 with extensive extrapulmonary injuries and general effects. General effects are mainly  
45 manifested in skeletal muscle consumption (SMW) and dysfunction (SMD), weight  
46 loss, cardiovascular complications, malnutrition, body composition change and so  
47 on.<sup>7-9</sup> As the amount of activity decreases, the muscle strength of each part of  
48 patient's body gradually weakens, the resistance decreases, and the symptom of  
49 dyspnea become serious, thus forming a vicious cycle from breathing difficulty to  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 activity reduction to aggravation of dyspnea,<sup>10,11</sup> finally resulting in accelerated  
4 deterioration of physical condition. Patients may gradually develop self-blame,  
5 inferiority, anxiety and depression.<sup>12</sup> In recent years, many studies have confirmed  
6 that anxiety and depression are the most common and most easily overlooked  
7 complications in COPD patients.<sup>13-15</sup> Anxiety and depression can, in turn, reduce the  
8 will of COPD patients, make them lose confidence in life, and reduce their medical  
9 aspirations and treatment compliance, as well as increase the number of acute  
10 exacerbations, hospitalization frequency and time.<sup>16</sup> Therefore, COPD has a serious  
11 impact on patients' physical health, mental well-being, and quality of life.  
12  
13  
14  
15  
16  
17  
18

19 Mindfulness is a state of consciousness, which is characterized by the  
20 self-regulation of attention to present moment experiences, acceptance of these  
21 experiences, and a non-judgmental position on these experiences.<sup>17</sup>  
22  
23  
24

25 Mindfulness-based interventions (MBIs) are usually short interventions (generally  
26 eight courses) provided in a group environment, including mindfulness meditation  
27 exercises and principles.<sup>18</sup>  
28  
29

30 Mindfulness interventions aim to raise awareness of present moment experience,  
31 help us to enjoy our daily experiences and manage our lives better. The common  
32 mindfulness interventions at present are mindfulness-based cognitive therapy  
33 (MBCT), mindfulness-based stress reduction (MBSR), and brief mindfulness  
34 meditation training intervention. There are also many MBIs which include  
35 mindfulness training exercises as part of a broader treatment program represented by  
36 acceptance and commitment therapy, dialectical behavior therapy, cognitive  
37 behavioral stress management, and integrative body-mind training, which have been  
38 proved to be beneficial to patients.  
39  
40  
41  
42  
43  
44  
45  
46

47 Current research have found that active meditation can not only enhance the  
48 perception of interoceptive information,<sup>19</sup> but also increase the accuracy of  
49 respiratory load<sup>20</sup>. Meditation may improve anxious COPD patients' ability to detect  
50 and monitor immediate ventilatory needs and respiratory load, improve their mental  
51 acuity, promote their active participation in daily life activities, and achieve better  
52  
53  
54  
55  
56

1  
2  
3 self-care management of disease.<sup>21-23</sup> However, study has found no significant  
4 improvement in the patient's 6 minute walk, the symptom burden and quality of life in  
5 COPD patients basing on an 8-week program of MBSR.<sup>24</sup>  
6  
7

8 Therefore, this study aims to evaluate the effectiveness and safety of MBIs for  
9 improving the psychological and physical conditions of COPD patients.  
10  
11

## 12 **METHODS And ANALYSIS**

### 13 **Study registration**

14 This meta-analysis protocol has been registered in the PROSPERO. The protocol will  
15 be strictly reported by the requirements of Preferred Reporting Items for Systematic  
16 Reviews and Meta-Analyses Protocols (PRISMA-P).<sup>25</sup>  
17  
18

### 19 **Inclusion criteria for study selection**

#### 20 **Types of included studies.**

21 All RCTs evaluating the efficacy of MBIs for COPD patients will be included in the  
22 study, and no restrictions on the language and time of publication. Others like animal  
23 mechanism studies, case reports, RCT protocol, non-RCTs, review articles ,  
24 repetitive study or meta-analysis will be excluded.  
25  
26

#### 27 **Participants.**

28 The participants with a clinical diagnosis of COPD were included in accordance with  
29 the global initiative for COPD,<sup>26</sup> the American Thoracic Society, the British Thoracic  
30 Society, the European Respiratory Society or Chinese COPD guideline.<sup>27</sup> in which  
31 patients with acute exacerbations within the 4 weeks before studies would be  
32 excluded.  
33

#### 34 **Intervention.**

35 The study aims at the effectiveness of MBIs for COPD patients. thus, different types  
36 of MBIs including MBSR, MBCT, acceptance and commitment therapy, brief  
37 mindfulness meditation training interventions, cognitive behavioral stress  
38 management, dialectical behavior therapy and integrative body-mind training will be  
39 covered. The intervention measures taken by the experimental group must be MBIs or  
40 MBIs combined with other treatment methods. The treatment of control group must  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56

1  
2  
3 be only therapies as usual or active comparison interventions, or combined with other  
4 treatment methods.

### 6 **Outcome measures.**

7  
8 The primary outcomes will include exercise capacity(e.g.6-minute walk test, bicycle  
9 cardiopulmonary exercise test) ,dyspnea, fatigue, scores of depression, scores of  
10 anxiety. And the secondary outcomes will include quality of life, scores of  
11 mindfulness and lung function (FVC and FEV1%).  
12  
13  
14  
15

### 16 **Search strategy**

17  
18 We will retrieve PubMed, Web of Science, Embase, the Cochrane Library and CNKI  
19 in accordance with each database rule specification. For each database, we have  
20 worked out a detailed search strategy to ensure all eligible studies. All databases  
21 search strategies are showed in Appendix A.  
22  
23  
24

### 25 **Data collection and analysis**

#### 26 **Studies selection .**

27  
28 The selection of research literature will be carried out independently by two  
29 researchers. First, make a preliminary selection by reading the abstract and title. Then,  
30 all relevant studies need to be downloaded in full and further selected according to the  
31 inclusion criteria. If the two researchers in the selection process have different  
32 opinions and fail to reach a consensus through discussion, the third researcher will  
33 make the final decisions. The selection process is displayed in the PRISMA flowchart  
34 (Fig. 1).  
35  
36  
37  
38  
39  
40

#### 41 **Data extraction .**

42  
43 Two researchers will independently conduct data extraction, which includes year of  
44 publication, authors, region, participants, study design, interventions both the  
45 observation group and the control intervention and outcomes. If the two researchers  
46 have different opinions and cannot to reach a consensus through discussion, the third  
47 researcher will make final decisions.  
48  
49  
50

#### 51 **Bias risk assessment.**

52  
53 For the bias risk in each study, we will evaluate it based on the Cochrane Handbook  
54 of Systematic Reviews of Interventions.<sup>28</sup> The content of the assessment involves the  
55  
56



1  
2  
3 random sequence generation, allocation concealment, blinding of participants and  
4 personnel, blinding of outcome assessment, incomplete outcome data, selective  
5 reporting and other bias. Two researchers will independently evaluate each study. If  
6 there are different opinions, the third researcher will make judgment and decision.  
7  
8  
9

### 10 **Statistical analysis**

11 We will conduct all data analysis by data statistics software of Review Manager 5.3.  
12 and Stata12.0..<sup>29</sup> the analysis of continuous variables by the mean difference (MD) or  
13 standardized mean difference (SMD) with 95% confidence intervals (CIs), and the  
14 analysis of classified variables by the risk ratio(RR) with 95% confidence intervals  
15 (CIs) . We will use the random effects model to conduct meta-analysis based on  
16 research recommendations.<sup>30</sup> Heterogeneity is calculated based on  $X^2$  test, and the  
17 judgement of heterogeneity degree depends on the  $I^2$  value( $I^2 >50\%$  or not)or  
18 P-value( $P < 0.10$  or not).<sup>31</sup> Sensitivity and subgroup analysis will be used to explore  
19 the source of heterogeneity. The potential publication bias of studies will be assessed  
20 by funnel plot combined with Egger's regression test.<sup>32</sup>  
21  
22  
23  
24  
25  
26  
27  
28  
29

### 30 **DISSCUSSION**

31 At present, our study should be the first time to systematically review the efficacy of  
32 MBIs in COPD patients comprehensively. It will provide a detailed overview of MBIs  
33 effective evidence for improving dyspnea, exercise capacity ,fatigue, depression,  
34 anxiety, lung function , quality of life and mindfulness levels of COPD patients. And  
35 the evidence may offer some help to patients, clinical medical workers and health  
36 policy makers concerning the application of MBIs in the treatment of COPD.  
37  
38  
39  
40  
41  
42  
43

### 44 **ETHICS AND DISSEMINATION**

45 This systematic review does not need to be examined and agreed by the ethics  
46 committee. And the results of the study will be exchanged as a conference paper or  
47 published in a journal.  
48  
49

50 **Contributors** T-LY is responsible for the writing of the entire manuscript. The  
51 electronic database retrieval strategy is formulated by T-LY and ZY. LL and WY will  
52 independently screen the research, extract the needed research data and assess the bias  
53  
54  
55  
56

1  
2  
3 risk. If LL and WY fail to reach an agreement in the above process, the final decision  
4 will be made by L -YL. The statistical analysis will be done by T-LY.

5  
6  
7 **Funding** This work was supported by Hunan provincial development and Reform  
8 Commission(the Project Grant No. [2016]65)

9  
10 **Competing interests** None declared.

11  
12 **Patient consent** This systematical review protocol does not require.

## 13 14 15 16 **REFERENCE**

- 17  
18 1. Liu W, Ge ZX, Li B. Study on Traditional Chinese Medicine Constitution Types of  
19 Patients with Acute Exacerbation of COPD with Secondary Pulmonary Fungal  
20 Infections ( AECOPD) and Prevention and Treatment. Chinese Journal of  
21 Experimental Traditional Medical Formulae 2013;19:321-4.  
22  
23 2. Cheng Y, Han X, Luo Y, et al. Analysis of co-morbidities of chronic obstructive  
24 pulmonary disease for patients in Yangpu District of Shanghai. Journal of Shanghai  
25 Jiao Tong University Medical Science 2015;35:82-5,96.  
26  
27 3. Murray CJ, Lopez AD, Mathers CD, et al. The Global Burden of Disease 2000  
28 project: aims, methods and data sources (GPE Discussion Paper No. 36). 2001.  
29  
30 4. HURD, Suzanne S, LENFANT, et al. Chronic obstructive pulmonary disease in five  
31 latin American cities (the PLATINO study) : a prevalence study. Commentary. Lancet  
32 2005;366:1875-81.  
33  
34 5. Zhong NS, Chen W, Yao WZ, et al. Prevalence of chronic obstructive pulmonary  
35 disease in China: a large, population-based survey. American Journal of Respiratory &  
36 Critical Care Medicine 2007;176:753-60.  
37  
38 6. Qian GS. Efforts on improving the diagnosis and treatment of respiratory diseases in  
39 China. Chinese Journal of lung disease (Electronic Version) 2015;5:1-3.  
40  
41 7. Pitta F, Troosters T, Spruit MA, et al. Characteristics of physical activities in daily  
42 life in chronic obstructive pulmonary disease. Am J Respir Crit Care Med  
43 2005;171:972-7.  
44  
45 8. Shrikrishna D, Patel M, Tanner RJ, et al. Quadriceps wasting and physical inactivity  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56

- 1  
2  
3 in patients with COPD. *European Respiratory Journal* 2012; 40:1115-22.
- 4  
5 9.Osthoff AK, Taeymans J, Kool J, et al. Association between peripheral muscle  
6 strength and daily physical activity in patients with COPD: a systematic literature  
7 review and meta-analysis. *Journal of Cardiopulmonary Rehabilitation & Prevention*  
8 2013; 33:351-9.
- 9  
10 10.Reardon JZ, Lareau SC, Zuwallack R. Functional status and quality of life in  
11 chronic obstructive pulmonary disease. *American Journal of Medicine* 2006;119:32-7.
- 12  
13 11.Zuwallack R. How Are You Doing? What Are You Doing? Differing Perspectives  
14 in the Assessment of Individuals with COPD[J]. *Copd Journal of Chronic Obstructive*  
15 *Pulmonary Disease* 2007; 4:293-7.
- 16  
17 12.Li JM, Cheng SZ, Zhang CH, et al. The effects of transitional care on the quality of  
18 life in patients with chronic obstructive pulmonary disease. *Chin J Nurs*  
19 2012;47:603-6.
- 20  
21 13.Li JX, Qiu XM, Wu CW. Correlation between BODE index of patients with  
22 chronic obstructive pulmonary disease and anxiety depression symptoms. *Journal of*  
23 *Clinical Pulmonary Medicine* 2016;21:460-3
- 24  
25 14. Maurer J, Rebbapragada V, Borson S, et al. Anxiety and depression in COPD:  
26 current understanding, unanswered questions, and research needs.[J]. *Chest*  
27 2008;134:43S.
- 28  
29 15. Norwood R. Prevalence and impact of depression in chronic obstructive  
30 pulmonary disease patients. *Current Opinion in Pulmonary Medicine* 2006;12:113-7.
- 31  
32 16.Laurin C, Moullec G, Bacon SL, et al. Impact of anxiety and depression on chronic  
33 obstructive pulmonary disease exacerbation risk. *American Journal of Respiratory &*  
34 *Critical Care Medicine* 2012;185:918-23.
- 35  
36 17.Bishop SR, Lau M, Shapiro S, et al. Mindfulness: A Proposed Operational  
37 Definition. *Clinical Psychology Science & Practice* 2010;11:230-41.
- 38  
39 18.Strauss C, Cavanagh K, Oliver A, et al. Mindfulness-based interventions for people  
40 diagnosed with a current episode of an anxiety or depressive disorder: a meta-analysis  
41 of randomised controlled trials. *Plos One* 2014;9:e96110.
- 42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56

- 1  
2  
3 19.Slagter HA, Lutz A, Greischar LL, et al. Theta Phase Synchrony and Conscious  
4 Target Perception: Impact of Intensive Mental Training. *Journal of Cognitive*  
5 *Neuroscience* 2009;21:1536-49.  
6  
7  
8 20. Daubenmier J, Sze J, Kerr CE, et al. Follow your breath: Respiratory interoceptive  
9 accuracy in experienced meditators. *Psychophysiology* 2013;50:777-89.  
10  
11 21.Kim YY, Choi JM, Kim SY, et al. Changes in EEG of children during brain  
12 respiration-training. *Am J Chin Med* 2002;30:405-17.  
13  
14 22.Chan AS, Han YMY, Cheung MC. Electroencephalographic (EEG) Measurements  
15 of Mindfulness-based Triarchic Body-pathway Relaxation Technique: A Pilot Study.  
16 *Applied Psychophysiology & Biofeedback* 2008;33:39-47.  
17  
18 23.Lutz A, Greischar LL, Rawlings NB, et al. Long-term meditators self-induce  
19 high-amplitude gamma synchrony during mental practice. *Proceedings of the National*  
20 *Academy of Sciences of the United States of America* 2004;101:16369-73.  
21  
22 24.Mularski RA, Munjas BA, Lorenz KA, et al. Randomized controlled trial of  
23 mindfulness-based therapy for dyspnea in chronic obstructive lung disease. *Journal of*  
24 *Alternative & Complementary Medicine* 2009;15:1083-90.  
25  
26 25.Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for  
27 systematic review and meta-analysis protocols (PRISMA-P) 2015:  
28 elaboration and explanation. *BMJ* 2015;350:g7647.  
29  
30 26. Global Strategy for the Diagnosis, Management and Prevention of  
31 COPD. Global Initiative for Chronic Obstructive Lung Disease: GOLD,  
32 2016. [http://www. goldcopd. org](http://www.goldcopd.org)  
33  
34 27.Group of Chronic Obstructive Pulmonary Disease, Branch of  
35 Respiratory Diseases, and Chinese Medical Association,. Guidance  
36 of diagnosis and treatment of chronic obstructive pulmonary disease  
37 (reversed edition in 2007),”. *Chin J Tuberc Respir Dis* 2007;30::8–17.  
38  
39 28. Higgins JPT, Green S (editors). *Cochrane Handbook for Systematic Reviews of*  
40 *Interventions* Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011.  
41 Available at:  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56


1  
2  
3 <http://www.equator-network.org/reporting-guidelines/cochrane-handbook-for-systematic-reviews-of-interventions-version-5-1-0/>

4  
5  
6  
7 29. Review Manager (RevMan) [Computer program]. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.

8  
9  
10 30. Furlan AD, Pennick V, Bombardier C, et al. 2009 Updated Method Guidelines for Systematic Reviews in the Cochrane Back Review Group. *Spine* 2009;34:1929-41.

11  
12  
13 31. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. *BMJ* 2003;327:557-60.

14  
15  
16  
17 32. StataCorp. Stata Statistical Software: Release 12. College Station, TX: StataCorp LP, 2011.



**Figure 1. Flow diagram of studies identified.**

## Appendix A

### Pubmed search strategy

- #1 randomized controlled trial[Publication Type]
- #2 Randomized Controlled Trials as Topic"[Majr]
- #3 random[Text Word]
- #4 RCT[Text Word]
- #5 controlled clinical trial[Publication Type]
- #6 Clinical Trials as Topic"[Majr]
- #7 Single-Blind Method"[Majr]
- #8 Double-Blind Method"[Majr]
- #9 single blind[Text Word]
- #10 double blind[Text Word]
- #11 placebo[Text Word]
- #12 allocation[Text Word]
- #13 random allocation[Text Word]
- #14 #1OR#2 OR #3OR#4 OR#5 OR#6 OR #7OR #8OR#9 OR#10 OR #11OR#12  
OR #13
- #15 "Pulmonary Disease, Chronic Obstructive"[Majr]
- #16 Airflow Obstruction[Title/Abstract] AND chronic[Title/Abstract]
- #17 COAD[Title/Abstract]
- #18 COPD[Title/Abstract]
- #19 Chronic Airflow Obstruction[Title/Abstract]
- #20 Chronic Obstructive Airway Disease[Title/Abstract]
- #21 Chronic Obstructive Lung Disease[Title/Abstract]
- #22 Chronic Obstructive Pulmonary Disease[Title/Abstract]
- #23 #15OR #16OR #17OR#18 OR#19 OR#20 OR#21 OR#22
- #24 "Mindfulness"[Majr]
- #25 Mindfulness[Title/Abstract]
- #26 Mindfulness-based cognitive therapy[Title/Abstract]
- #27 MBCT[Text Word]
- #28 mindfulness-based stress reduction[Title/Abstract]
- #29 MBSR[Text Word]
- #30 "Meditation"[Majr]
- #31 meditation[Title/Abstract]
- #32 mindfulness meditation[Title/Abstract]
- #33 acceptance[Title/Abstract] AND commitment therapy[Title/Abstract]
- #34 dialectical behavior therapy[Title/Abstract]
- #35 cognitive behavioral stress management[Title/Abstract]
- #36 integrative body–mind training[Title/Abstract]

#37 mindfulness-related interventions[Title/Abstract]  
 #38 Vipassana[Title/Abstract]  
 #39 Zen[Title/Abstract]  
 #40 mantra meditation[Title/Abstract]  
 #41 #24 OR#25 OR #26OR#27 OR#28 OR #29OR#30 OR #31OR #32OR#33 OR  
 #34OR#35 OR#36 OR #37OR#38 OR #39OR #40  
 #42 "Humans"[Majr]  
 #43 "Animals"[Majr]  
 #44 #42NOT#43  
 #45 #15 AND #23 AND #41 AND #44

### Embase search strategy

#1 'randomization'/exp OR 'placebo'/exp OR 'placebo effect'/exp OR 'single blind  
 procedure'/exp OR 'double blind procedure'/exp OR 'randomized controlled trial'/exp  
 OR 'randomized controlled trial (topic)'/exp OR 'controlled clinical trial'/exp  
 OR 'controlled clinical trial (topic)'/exp OR 'clinical trial'/exp OR 'clinical trial  
 (topic)'/exp  
 #2 random\*:ab,ti OR allocation:ab,ti OR placebo:ab,ti OR single AND blind:ab,ti  
 OR double AND blind:ab,ti OR rct:ab,ti OR clinical AND trial\*:ab,ti  
 #3 #1 OR #2  
 #4 'Chronic Airflow Obstruction':ab,ti OR 'Chronic Obstructive Airway Disease  
 ':ab,ti OR 'Chronic Obstructive Lung Disease ':ab,ti 'Chronic Obstructive Pulmonary  
 Disease ':ab,ti OR 'COAD ':ab,ti OR 'COPD ':ab,ti  
 #5 'Mindfulness':ab,ti OR 'Mindfulness-based cognitive therapy ':ab,ti OR '  
 MBCT ':ab,ti 'mindfulness-based stress reduction':ab,ti OR 'MBSR ':ab,ti  
 OR 'meditation ':ab,ti OR 'mindfulness meditation':ab,ti OR 'acceptance commitment  
 therapy':ab,ti OR 'dialectical behavior therapy':ab,ti 'cognitive behavioral stress  
 management':ab,ti OR 'integrative body–mind training':ab,ti OR 'mindfulness-related  
 interventions':ab,ti OR 'Vipassana':ab,ti OR 'Zen':ab,ti OR 'mantra  
 meditation':ab,ti  
 #6 #3 AND #4 AND #5

### The Cochrane Library search strategy

#1 "random\*" or allocation or "random allocation" or placebo or single blind or  
 double blind or "randomized controlled trial\*" or RCT or "clinical trial \*"  
 #2 randomized controlled trial:pt or clinical trial:pt  
 #3 #1 or #2  
 #4 Chronic Airflow Obstruction:ti,ab,kw or Chronic Obstructive Airway  
 Disease:ti,ab,kw or Chronic Obstructive Lung Disease:ti,ab,kw or Chronic  
 Obstructive Pulmonary Disease:ti,ab,kw or COAD:ti,ab,kw or COPD:ti,ab,kw  
 #5 Mindfulness:ti,ab,kw or Mindfulness-based cognitive therapy:ti,ab,kw or  
 MBCT:ti,ab,kw or mindfulness-based stress reduction:ti,ab,kw or MBSR:ti,ab,kw or



1  
2  
3 meditation:ti,ab,kw or mindfulness meditation:ti,ab,kw or acceptance commitment  
4 therapy:ti,ab,kw or dialectical behavior therapy:ti,ab,kw or cognitive behavioral stress  
5 management:ti,ab,kw or integrative body–mind training:ti,ab,kw or  
6 mindfulness-related interventions:ti,ab,kw or Vipassana:ti,ab,kw or Zen:ti,ab,kw or  
7 mantra meditation:ti,ab,kw  
8  
9 #6 #3 and #4 and #5  
10  
11  
12

### 13 **Web of science search strategy**

14 #1 TS=("random \*" OR allocation OR "random allocation" OR placebo OR single  
15 blind OR single blind method OR double blind OR double blind method OR  
16 "randomized controlled trial\*" OR "randomized controlled trial\*" OR "RCT" OR  
17 "clinical trial \*")

18  
19 #2 TS=( Chronic Airflow Obstruction OR Chronic Obstructive Airway Disease OR  
20 Chronic Obstructive Lung Disease OR Chronic Obstructive Pulmonary Disease OR  
21 COAD OR COPD )

22 #3 TS=( Mindfulness OR Mindfulness-based cognitive therapy OR MBCT OR  
23 mindfulness-based stress reduction OR MBSR OR meditation OR mindfulness  
24 meditation OR acceptance commitment therapy OR dialectical behavior therapy OR  
25 cognitive behavioral stress management OR integrative body–mind training OR  
26 mindfulness-related interventions OR Vipassana OR Zen OR mantra meditation)

27  
28 #4 #3 AND #2 AND #1  
29  
30

### 31 **CNKI search strategy**

32 (SU = '随机' OR SU = '随机分配' OR SU = '随机对照' OR SU = '对照' OR SU = '盲法' OR  
33  
34 SU = '单盲' OR SU = '双盲' OR SU = '随机对照实验' OR SU = '随机对照研究' OR SU =  
35  
36 'RCT' OR SU = '临床试验' OR SU = '临床研究' OR SU = '临床观察' OR SU = '临床试验')  
37  
38 AND ( SU = '慢性阻塞性肺炎' OR SU = '慢性阻塞性肺部疾病' OR SU = 'COPD' OR SU =  
39  
40 'COAD') AND ( SU = '正念' OR SU = '冥想' OR SU = '正念认知疗法' OR SU = ' MBCT'  
41  
42 OR SU = '正念减压疗法' OR SU = 'MBSR' OR SU = '正念冥想' OR SU = '接受与承诺疗法'  
43  
44 OR SU = '辩证行为疗法' OR SU = '认知行为压力管理' OR SU = '整合身心训练' OR SU = '  
45  
46 内观' OR SU = '禅' OR SU = '曼陀罗禅修')  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

|

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

**PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 checklist: recommended items to address in a systematic review protocol\***

Section and topic	Item No	Checklist item	Reported on page#
<b>ADMINISTRATIVE INFORMATION</b>			
Title:			
Identification	1a	Identify the report as a protocol of a systematic review	1
Update	1b	If the protocol is for an update of a previous systematic review, identify as such	
Registration	2	If registered, provide the name of the registry (such as PROSPERO) and registration number	2
Authors:			
Contact	3a	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author	1
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review	7-8
Amendments	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	N/A
Support:			
Sources	5a	Indicate sources of financial or other support for the review	8
Sponsor	5b	Provide name for the review funder and/or sponsor	8
Role of sponsor or funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol	8
<b>INTRODUCTION</b>			
Rationale	6	Describe the rationale for the review in the context of what is already known	3-5
Objectives	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	3-5
<b>METHODS</b>			

Eligibility criteria	8	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review	5
Information sources	9	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage	6
Search strategy	10	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated	13-15
Study records:			
Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review	6
Selection process	11b	State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)	6
Data collection process	11c	Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators	6
Data items	12	List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications	6
Outcomes and prioritization	13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale	6
Risk of bias in individual studies	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis	6-7
Data synthesis	15a	Describe criteria under which study data will be quantitatively synthesised	7
	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as $I^2$ , Kendall's $\tau$ )	7
	15c	Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression)	7
	15d	If quantitative synthesis is not appropriate, describe the type of summary planned	7

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

Meta-bias(es)	16	Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies)	7
Confidence in cumulative evidence	17	Describe how the strength of the body of evidence will be assessed (such as GRADE)	N/A

**\* It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0.**

*From: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015 Jan 2;349(jan02 1):g7647.*

# BMJ Open

## The Efficacy of Mindfulness-Based Interventions for COPD Patients: A systematic study and meta-analysis protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-026061.R1
Article Type:	Protocol
Date Submitted by the Author:	13-Nov-2018
Complete List of Authors:	tian, lingyun; Central South University, Xiangya Nursing School; Anhui University of Chinese Medicine, School of Nursing zhang, ying; Central South University, Department of infection control , Xiangya hospital li, li; Central South University, Department of nursing, Xiangya hospital wu, ying; Central South University, Department of burn, Xiangya hospital Li, Ying-lan; Central South University, Department of nursing, Xiangya hospital
<b>Primary Subject Heading</b>:	Evidence based practice
Secondary Subject Heading:	Respiratory medicine
Keywords:	MEDICAL EDUCATION & TRAINING, Chronic airways disease < THORACIC MEDICINE, Protocols & guidelines < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Quality in health care < HEALTH SERVICES ADMINISTRATION & MANAGEMENT

SCHOLARONE™  
Manuscripts

1  
2  
3  
4 **The Efficacy of Mindfulness-Based Interventions for COPD Patients: A**  
5 **systematic study and meta-analysis protocol**  
6  
7

8 Lingyun Tian<sup>1, 2</sup>, Ying Zhang<sup>3</sup>, Li Li<sup>4</sup>, Ying Wu<sup>5</sup>, Yinglan Li<sup>4</sup>  
9

10 1 Xiangya Nursing School, Central South University, Changsha, China  
11

12  
13 2 School of Nursing, Anhui University of Chinese Medicine, Hefei, China  
14

15  
16 3 Department of infection control , Xiangya hospital, Central South University,  
17 Changsha, China  
18

19  
20  
21 4 Department of nursing, Xiangya hospital, Central South University, Changsha,  
22 China  
23

24  
25  
26 5 Department of burn, Xiangya hospital, Central South University, Changsha, China  
27  
28  
29  
30

31 **Email:**  
32

33  
34 Lingyun Tian: tianlingyun@csu.edu.cn  
35

36  
37 Ying Zhang: 350208667@qq.com  
38

39  
40 Li Li: 468053702@qq.com  
41

42  
43 Ying Wu: wuying2341@126.com  
44

45  
46 Yinglan Li: yuyan0202@sina.com  
47

48 **correspondence to professor Yinglan Li**  
49

50  
51 **Address:** 87 Xiang Ya Road Changsha 410008 Hunan, China  
52  
53

54 **Word count:** 4796  
55  
56  
57  
58  
59  
60

## Abstract

**Introduction** Chronic obstructive pulmonary disease (COPD) is a common chronic respiratory disease. It has adverse effects on patients' physical health, mental well-being and life quality. The purpose of mindfulness-based interventions (MBIs) is to raise non-judgemental awareness and attention to the current internal and external experience. Namely the attention is shifted from the perceived and involuntary inner activities to current experience, keeping more curious, open and accepting attitudes towards current experience. Although some studies on the intervention effect of MBIs in COPD patients have been conducted, whose results are controversial, especially on the dyspnea, the level of mindfulness and life quality. Therefore, the systematical study of MBIs in COPD patients is required to provide the available evidence for the further study.

**Methods and analyses** In this study, different studies from various databases will be involved. Randomized controlled trials (RCTs), qualitative studies and case studies on the effect of MBIs in COPD patients aged over 18 will be concluded. We will search the literature search from the databases of PubMed, Embase, Web of Science, CINAHL, the Cochrane Library, PsycINFO and China National Knowledge



1  
2  
3  
4 Infrastructure (CNKI). The primary outcomes will include the MBIs efficacy for  
5 COPD patients in terms of the dyspnea, depression and anxiety. The secondary  
6 outcomes will include that in terms of life quality, mindful awareness, 6-minute walk  
7 test and nutritional risk index. Data extraction will be conducted by two researchers  
8 independently, and bias risk of the meta-analysis will be evaluated based on the  
9 Cochrane Handbook of Systematic Reviews of Interventions. All data analyses will be  
10 conducted by data statistics software of Review Manager 5.3. and Stata12.0.  
11  
12  
13  
14  
15  
16  
17

18 **Ethics and dissemination** The examination and agreement of the ethics committee  
19 are not required in this study. We intend to publish the study results in a journal or  
20 conference presentations.  
21  
22  
23  
24

25 **PROSPERO registration number** CRD42018102323  
26  
27  
28  
29  
30  
31  
32

### 33 **Strengths and limitations of this study**

- 34 ● This study provides a detailed and evidence-based study on the efficacy of MBIs  
35 in COPD patients.
- 36 ● Extensive search strategies and inclusion criteria will be included in this study,  
37 indicating a comprehensive narrative of the available evidence.
- 38 ● Data extraction and bias risk of studies involved in the meta-analysis will be  
39 independently conducted.
- 40 ● Sensitivity and subgroup analysis will be used to explore the source of  
41 heterogeneity for the meta-analysis, and the potential publication bias will be  
42 assessed by the funnel plot combined with Egger's regression tests.
- 43 ● Although detailed retrieval strategies have been formulated in our study,  
44 unpublished trials may not be included.
- 45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## INTRODUCTION

As a common disease, chronic obstructive pulmonary disease (COPD) is characterized by persistent and progressive airflow limitation, accompanied by an increase in chronic inflammatory responses caused by harmful particles or gases in the airway and lungs. Besides, the acute exacerbation and comorbidities affect the overall severity of this disease.<sup>1</sup> Due to the high mortality, COPD endangers patients' health and lives, placing a heavy financial burden on their families and society.<sup>2</sup>

It is reported that the incidence of COPD is about 10% in the worldwide.<sup>3</sup> COPD might jump from the fourth to the third cause of the global death by 2020, ranking the fifth in the global economic burden.<sup>4</sup> An epidemiological survey of COPD in China shows that the prevalence rate of COPD is 8.2% for people older than 40 years old, the number of death and disabled caused by COPD are more than 1 million and 5~10 million a year.<sup>5</sup> In rural areas, the mortality rate of respiratory diseases ranks first among all causes of death in China.<sup>6</sup>

COPD has a serious impact on patients' physical health, mental well-being and life quality. General adverse physiological effects are mainly manifested in skeletal muscle consumption (SMW) and dysfunction (SMD), weight loss, cardiovascular complications, malnutrition and body composition change.<sup>7-9</sup> With the decreased amount of activity, the muscle strength and resistance of the patient's body are gradually weakened, and the symptom of dyspnea becomes more serious. Thus, a vicious cycle is formed, namely from the breathing difficulty to activity reduction to the dyspnea aggravation, finally resulting in accelerated deterioration of physical condition.<sup>10 11</sup> Besides, mood disorders are common symptoms among COPD patients. In recent years, studies have confirmed that anxiety and depression are the most common and most easily overlooked complications in COPD patients.<sup>12-14</sup> Anxiety and depression can discourage patients in their lives, reduce their confidence in medical aspirations and treatment compliance, in turn the number of acute

1  
2  
3  
4 exacerbations, hospitalization frequency and time are increased with greater disability  
5 and dyspnoea.<sup>15 16</sup> Life quality is a key indicator for estimating the disease burden,  
6 especially for chronic diseases.<sup>17</sup> Research has indicated that COPD patients may  
7 have a poor life quality.<sup>17 18</sup> Depressive symptoms negatively influence their mental  
8 life quality, and dyspnea often interferes with their health-related life quality.<sup>18 19</sup>  
9  
10  
11  
12  
13

14 Mindfulness-based interventions (MBIs) are usually referred to short interventions  
15 (generally eight courses) provided in a group environment, including mindfulness  
16 meditation exercises and principles.<sup>20</sup> The purpose of MBIs is to raise  
17 non-judgemental awareness and attention to the current internal and external  
18 experience. Namely the attention is shifted from the perceived and involuntary inner  
19 activities to current experience, keeping more curious, open and accepting attitudes  
20 toward current experience.<sup>21-23</sup> Present mindfulness interventions include  
21 mindfulness-based cognitive therapy (MBCT), mindfulness-based stress reduction  
22 (MBSR), and brief mindfulness meditation training intervention.<sup>24</sup> There are also  
23 other MBIs which include mindfulness training exercises as a part of treatment  
24 program, such as the acceptance and commitment therapy, compassion focused  
25 therapy, dialectical behavior therapy, integrative body-mind training and cognitive  
26 behavioral stress management.<sup>24 25</sup> These methods have been proved to be beneficial to  
27 patients.<sup>24 25</sup>  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41

42 It is proved that mindfulness interventions can reduce symptoms of chronic disease  
43 and improve accurate symptom assessment, which may improve disease management  
44 and well-being in patients with COPD.<sup>26</sup> The following themes are proposed in the  
45 qualitative evidence on MBCT positive effect of anxious and depressed asthma and  
46 COPD patients: combine lung rehabilitation advice with mindfulness; greater  
47 acceptance and reduction of disease-related stigma; developing a new relationship  
48 between breathing, activity and related thoughts; noticing subtle physical sensations  
49 and early signs of difficulty breathing; being creative with limitations and removing  
50 mental barriers to become more active; having a stronger sense of control.<sup>27</sup>  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 It is verified that mindfulness interventions are effective in improving the mindful  
5 awareness, CD3<sup>+</sup> T cell number, CD4<sup>+</sup> T cell number<sup>28</sup> and depression in COPD,<sup>29</sup>  
6 reducing the nutritional risk index and CD8<sup>+</sup> T cell number<sup>28</sup>. Systematic health  
7 education combined mindfulness interventions can lower the dyspnea and the  
8 nutritional risk index, improve the mindful awareness, compared with the only used  
9 systematic health education intervention.<sup>30</sup> A 10-minute mindfulness intervention in  
10 COPD patients has shown that there is a changing tendency in outcomes of the  
11 intervention group, including depression, anxiety, happiness, dyspnoea, mindfulness  
12 and stress. While no significant difference exists among groups, most participants  
13 supposed that the mindfulness interventions are useful and they are glad to  
14 recommend it.<sup>16</sup> It is concluded that meditation may improve the detection ability,  
15 monitor immediate ventilatory needs and respiratory load, improve the mental acuity,  
16 promote their active participation in daily life activities, and achieve better self-care  
17 management of disease for anxious COPD patients.<sup>31-33</sup> MBSR is verified to improve  
18 the life quality of veterans with chemical lung injury, but not their lung function<sup>34</sup>.  
19 However, compared with the support group, no significant improvement is observed  
20 in exacerbation rates of the RCT trial, health-related life quality measures,  
21 mindfulness, 6MWT distance, dyspnea, stress, or symptom scores for COPD patients  
22 after receiving the mindfulness-based breathing therapy<sup>35</sup>.

23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41 In 2016, a systematic study was conducted to examine the effect of mindfulness  
42 on mindful awareness, health-related life quality and stress in adults with respiratory  
43 illnesses. In this meta-analysis, three studies propose that mindfulness cannot improve  
44 the health-related life quality, while other two studies claim that mindfulness can not  
45 improve the level of mindfulness and relieve stress. Different conclusions are largely  
46 caused by the inconsistent research methodologies<sup>36</sup>. In the former study of adult  
47 respiratory diagnosis published in 2016, three outcomes were obtained for the MBSR  
48 intervention. In this paper, COPD patients with different types of MBIs and more  
49 outcomes are investigated. Considering the small number of eligible studies, we  
50 intended to involve RCTs/quantitative designs, qualitative studies and case studies in  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 this study to describe the application status of MBIs in COPD patients. Besides,  
5 meta-analyses should be only performed on the basis of RCTs.  
6  
7

8 The updated systematic study and meta-analysis is performed for two  
9 objectives:(1) describe the application status of MBIs delivered for COPD patients  
10 and (2) examine the effect of MBIs on outcomes including depression, anxiety, life  
11 quality, mindful awareness, 6-minute walk test and nutritional risk index.  
12  
13  
14  
15

## 16 17 **METHODS And ANALYSIS**

### 18 19 **Study registration**

20 This systematic study and meta-analysis protocol have been registered in the  
21 PROSPERO. The protocol is strictly reported by the requirements of Preferred  
22 Reporting Items for Systematic Reviews and Meta-Analyses Protocols  
23 (PRISMA-P).<sup>37</sup>  
24  
25  
26  
27  
28  
29

### 30 31 **Inclusion criteria for study selection**

#### 32 33 **Types of included studies**

34 For the meta-analytic purpose of objective 2, all RCTs evaluating the efficacy of  
35 MBIs in COPD patients will be included in the study. In addition, we intend to add  
36 qualitative studies and case studies for describing the application status of MBIs in  
37 patients with COPD of objective 1. No restrictions on the language and time of  
38 publication. Others like animal mechanism studies, RCT protocol, repetitive study  
39 will be excluded.  
40  
41  
42  
43  
44  
45  
46  
47

#### 48 49 **Participants**

50 Patients aged at least 18 years old with a clinical diagnosis of COPD confirmed by  
51 postbronchodilator forced expiratory volume in 1 second (FEV<sub>1</sub>) <80% of the  
52 predicted value in combination with an FEV<sub>1</sub> =forced vital capacity <70% in  
53 accordance with the global initiative for COPD,<sup>38</sup> the American Thoracic Society, the  
54 British Thoracic Society, the European Respiratory Society or Chinese COPD  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 guideline<sup>39</sup> will be included.  
5

## 6 **Intervention**

7  
8  
9 The study aims at the efficacy of MBIs in COPD patients. Thus, different types of  
10 MBIs should be covered, including MBSR, MBCT, acceptance and commitment  
11 therapy, brief mindfulness meditation training interventions, cognitive behavioral  
12 stress management, dialectical behavior therapy, integrative body-mind training and  
13 compassion focused therapy etc. The intervention measures taken by the experimental  
14 group must be MBIs or MBIs with other combined treatment methods. The treatment  
15 of control group must be the only therapy as usual or active comparison interventions,  
16 or combined with other treatment methods.  
17  
18  
19  
20  
21  
22  
23  
24

## 25 **Outcome measures**

26  
27  
28 The primary outcomes will include the MBIs efficacy for COPD patients in terms of  
29 the dyspnea, depression, anxiety. The secondary outcomes will include that in terms  
30 of life quality, mindful awareness, 6-minute walk test and nutritional risk index.  
31  
32  
33  
34

## 35 **Search strategy**

36  
37  
38 We intend to retrieve the literature search from PubMed, Web of Science, Embase,  
39 the Cochrane Library, CINAHL, PsycINFO, and CNKI in accordance with database  
40 rules. During the literature retrieval, information expert and lung diseases expert have  
41 offered the help and guidance. To fully retrieve the eligible studies, a comprehensive  
42 retrieval strategy will be adopted, combining with MeSH terms, text word, title/abstract  
43 and synonyms. These detailed search strategies for different databases are shown in  
44 Appendix A.  
45  
46  
47  
48  
49  
50

## 51 **Data collection and analyses**

### 52 **Studies selection**

53  
54  
55 The selection of research literature will be independently carried out by two  
56 researchers. Firstly, we will make a preliminary selection by reading the abstract and  
57  
58  
59  
60

1  
2  
3  
4 title. Secondly, we will download all relevant studies for the further selection  
5 according to the inclusion criteria. If there is a different opinion between two  
6 researchers, the issue will be discussed to reach an agreement. If it fails to reach a  
7 consensus through discussion, the third researcher will make the final decisions. The  
8 selection process is displayed in the PRISMA flowchart (Fig. 1).  
9  
10  
11  
12

### 13 14 **Data extraction**

15  
16 We will explore the characteristics of different studies qualitatively. Data extraction  
17 will be dependently conducted by two researchers, including the publication time,  
18 authors, region, participants (n, gender and age), study design, intervention methods,  
19 intervention duration, outcomes, assessment method, significant findings and duration  
20 of follow-up. If two researchers have different opinions and cannot to reach a  
21 consensus through discussion, the third researcher will make final decisions.  
22  
23  
24  
25  
26  
27  
28

### 29 **Bias risk assessment**

30  
31 To evaluate bias risk in the meta-analysis, all studies involved in the meta-analysis  
32 will be evaluated based on the Cochrane Handbook of Systematic Reviews of  
33 Interventions.<sup>40</sup> Assessment items will involve the random sequence generation,  
34 allocation concealment, blinding of participants and personnel, blinding of outcome  
35 assessment, incomplete outcome data, selective reporting and other bias. If there are  
36 different opinions, the third researcher will make the final decision.  
37  
38  
39  
40  
41  
42  
43

### 44 **Statistical analysis**

45  
46 We will conduct data analyses by data statistics software of Review Manager 5.3. and  
47 Stata12.0.<sup>41</sup> The continuous variables will be analyzed by the mean difference (MD)  
48 or standardized mean difference (SMD) with 95% confidence intervals (CIs), and  
49 classified variables will be analyzed by the risk ratio(RR) with 95% confidence  
50 intervals (CIs). We will use the random effects model to conduct the meta-analysis  
51 based on research recommendations.<sup>42</sup> Heterogeneity will be calculated based on the  
52  $X^2$  test, and the judgement of heterogeneity degree will be depended on the  $I^2$  value( $I^2$ )  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 >50% or not) or P-value( $P < 0.10$  or not).<sup>43</sup> We will use sensitivity and subgroup  
5 analysis to explore the source of heterogeneity. The following subgroup analyses will  
6 be performed on different types of MBIs (e.g. MBSR, MBCT, acceptance  
7 commitment therapy, meditation, dialectical behavior therapy and cognitive  
8 behavioral stress management etc), types of patients, intervention duration and  
9 duration of follow-up. The potential publication bias of all used studies in the  
10 meta-analysis will be assessed by funnel plot combined with Egger's regression test.<sup>44</sup>  
11  
12  
13  
14  
15  
16  
17

### 18 **Patient and public involvement**

19  
20  
21 We currently collect data from previously published studies in this study protocol of a  
22 meta-analysis, hence no patients and the general public has been involved in.  
23  
24

### 25 **DISCUSSION**

26  
27  
28 This study aims to systematically review the efficacy of MBIs in COPD patients. It  
29 will provide a detailed and evidence-based overview of the effect of MBIs on  
30 improving COPD patients' dyspnea, depression, anxiety, life quality, mindful  
31 awareness, 6-minute walk test and nutritional risk index. This result will provide an  
32 evidence-based basis for clinical practitioners in selecting mindfulness-based  
33 therapies for COPD patients, and offer patients with appropriate personalized  
34 interventions.  
35  
36  
37  
38  
39  
40  
41  
42

43 **Contributors** T-LY is responsible for the writing of the entire manuscript. The  
44 electronic database retrieval strategy is formulated by T-LY and ZY. LL and WY will  
45 independently screen the research, extract the needed research data and assess the bias  
46 risk. If LL and WY fail to reach an agreement in the above process, the final decision  
47 will be made by L -YL. The statistical analysis will be performed by T-LY.  
48  
49  
50  
51  
52

53 **Funding** This work is supported by Hunan provincial development and reform  
54 commission (the Project Grant No. [2016]65) and Hunan Provincial Social Science  
55 Foundation (the Project Grant No.14YBA404)  
56  
57  
58  
59

60 **Competing interests** None declared.



1  
2  
3  
4 **Patient consent** It is not required in this systematical study protocol.  
5  
6  
7  
8

9 **REFERENCE**  
10

- 11  
12 1. Cheng Y, Han X, Luo Y, et al. Analysis of co-morbidities of chronic obstructive  
13 pulmonary disease for patients in Yangpu District of Shanghai. *Journal of Shanghai*  
14 *Jiao Tong University Medical Science* 2015;35:82-5,96.  
15  
16  
17  
18 2. Liu W, Ge ZX, Li B. Study on Traditional Chinese Medicine Constitution Types of  
19 Patients with Acute Exacerbation of COPD with Secondary Pulmonary Fungal  
20 Infections ( AECOPD) and Prevention and Treatment. *Chinese Journal of*  
21 *Experimental Traditional Medical Formulae* 2013;19:321-4.  
22  
23  
24  
25  
26  
27 3. HURD, Suzanne S, LENFANT, et al. Chronic obstructive pulmonary disease in  
28 five latin American cities (the PLATINO study) : a prevalence study. *Commentary.*  
29 *Lancet* 2005;366:1875-81.  
30  
31  
32  
33  
34 4. Murray CJ, Lopez AD, Mathers CD, et al. The Global Burden of Disease 2000  
35 project: aims, methods and data sources (GPE Discussion Paper No. 36). 2001.  
36  
37  
38  
39 5. Zhong NS, Chen W, Yao WZ, et al. Prevalence of chronic obstructive pulmonary  
40 disease in China: a large, population-based survey. *American Journal of Respiratory*  
41 *& Critical Care Medicine* 2007;176:753-60.  
42  
43  
44  
45 6. Qian GS. Efforts on improving the diagnosis and treatment of respiratory diseases in  
46 China. *Chinese Journal of lung disease (Electronic Version)* 2015;5:1-3.  
47  
48  
49  
50 7. Pitta F, Troosters T, Spruit MA, et al. Characteristics of physical activities in daily  
51 life in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*  
52 *2005;171:972-7.*  
53  
54  
55  
56 8. Shrikrishna D, Patel M, Tanner RJ, et al. Quadriceps wasting and physical inactivity  
57 in patients with COPD. *Eur Respir J* 2012; 40:1115-22.  
58  
59  
60

- 1  
2  
3  
4 9.Osthoff AK, Taeymans J, Kool J, et al. Association between peripheral muscle  
5 strength and daily physical activity in patients with COPD: a systematic literature  
6 review and meta-analysis. *J Cardiopulm Rehabil Prev* 2013; 33:351-9.  
7  
8  
9  
10 10.Reardon JZ, Lareau SC, Zuwallack R. Functional status and quality of life in  
11 chronic obstructive pulmonary disease. *Am J Med* 2006;119:32-7.  
12  
13  
14 11.Zuwallack R. How Are You Doing? What Are You Doing? Differing Perspectives  
15 in the Assessment of Individuals with COPD.*COPD* 2007; 4:293-7.  
16  
17  
18 12.Li JX, Qiu XM, Wu CW. Correlation between BODE index of patients with  
19 chronic obstructive pulmonary disease and anxiety depression symptoms. *Journal of*  
20 *Clinical Pulmonary Medicine* 2016;21:460-3  
21  
22  
23  
24 13. Maurer J, Rebbapragada V, Borson S, et al. Anxiety and depression in COPD:  
25 current understanding, unanswered questions, and research needs.[J]. *Chest*  
26 2008;134:43S.  
27  
28  
29  
30  
31  
32 14. Norwood R. Prevalence and impact of depression in chronic obstructive  
33 pulmonary disease patients. *Curr Opin Pulm Med* 2006;12:113-7.  
34  
35  
36  
37 15.Laurin C, Moullec G, Bacon SL, et al. Impact of anxiety and depression on chronic  
38 obstructive pulmonary disease exacerbation risk.*Am J Respir Crit Care*  
39 *Med* 2012;185:918-23.  
40  
41  
42  
43 16.Perkins-Porras L, Riaz M, Okekunle A, et al. Feasibility study to assess the effect  
44 of a brief mindfulness intervention for patients with chronic obstructive pulmonary  
45 disease: a randomized controlled trial. *Chron Respir Dis* 2018;15:400-10  
46  
47  
48  
49  
50 17.Pengpid S, Peltzer K.The Impact of Chronic Diseases on the Quality of Life of  
51 Primary Care Patients in Cambodia, Myanmar and Vietnam.*Iran J Public*  
52 *Health* 2018; 47:1308-16.  
53  
54  
55  
56 18.Ivziku D1,2, Clari M3, Piredda M4,et al.Anxiety, depression and quality of  
57 life in chronic obstructive pulmonary disease patients and caregivers: an actor-partner  
58  
59  
60

- 1  
2  
3  
4 interdependence model analysis. *Qual Life Res* 2018. doi:  
5 10.1007/s11136-018-2024-z. [Epub ahead of print]  
6  
7  
8 19. Ries AL. Impact of chronic obstructive pulmonary disease on quality of life: the  
9 role of dyspnea. *Am J Med* 2006 ;119:12-20.  
10  
11  
12 20. Strauss C, Cavanagh K, Oliver A, et al. Mindfulness-based interventions for  
13 people diagnosed with a current episode of an anxiety or depressive disorder: a  
14 meta-analysis of randomised controlled trials. *Plos One* 2014;9:e96110.  
15  
16  
17 21. Brown KW, Ryan RM. The benefits of being present: mindfulness and its role in  
18 psychological well-being. *J Pers Soc Psychol* 2003;84:822-48.  
19  
20  
21 22. Williams JM, Teasdale JD, Segal ZV, et al. Mindfulness-based cognitive  
22 therapy reduces overgeneral autobiographical memory in formerly depressed  
23 patients. *J Abnorm Psychol* 2000;109:150-5.  
24  
25  
26 23. Bishop SR, Lau M, Shapiro S, et al. Mindfulness: A Proposed Operational  
27 Definition. *Clinical Psychology Science & Practice* 2010;11:230-41.  
28  
29  
30 24. Creswell J D. Mindfulness Interventions. *Annual Review of Psychology*  
31 2016;68:491-516.  
32  
33  
34  
35 25. Craig C, Hiskey S, Royan L, et al. Compassion focused therapy for people with  
36 dementia: A feasibility study. *Int J Geriatr Psychiatry*. 2018. doi: 10.1002/gps.4977.  
37 [Epub ahead of print]  
38  
39  
40 26. Chan RR, Giardino N, Larson JL. A pilot  
41 study: mindfulness meditation intervention in COPD. *Int J Chron Obstruct Pulmon*  
42 *Dis* 2015;10:445-54.  
43  
44  
45  
46 27. Malpass A, Kessler D, Sharp D, et al. MBCT for Patients with Respiratory  
47 Conditions Who Experience Anxiety and Depression: A Qualitative Study.  
48 *Mindfulness* 2015; 6:1-11.  
49  
50  
51  
52 28. Li JN, Guo X, Wang HY. Application of mindfulness intervention in health  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 education on patients with pulmonary tuberculosis complicated with COPD. Chinese  
5 Nursing Research 2015;29:2983-6.  
6

7  
8 29. Panagioti M, Scott C, Blakemore A, et al. Overview of the prevalence, impact, and  
9 management of depression and anxiety in chronic obstructive pulmonary disease. *Int J  
10 Chron Obstruct Pulmon Dis* 2014;9:1289-306.  
11  
12

13  
14 30. Wang DM. Effect of systematic health education combined with mindful behavior  
15 nursing intervention on patients with tuberculosis combined with COPD. *Laboratory  
16 Medicine and Clinic* 2017;14:1819-21.  
17  
18

19  
20 31. Kim YY, Choi JM, Kim SY, et al. Changes in EEG of children during brain  
21 respiration-training. *Am J Chin Med* 2002;30:405-17.  
22  
23

24  
25 32. Chan AS, Han YMY, Cheung MC. Electroencephalographic (EEG) Measurements  
26 of Mindfulness-based Triarchic Body-pathway Relaxation Technique: A Pilot Study.  
27 *Applied Psychophysiology & Biofeedback* 2008;33:39-47.  
28  
29

30  
31 33. Lutz A, Greischar LL, Rawlings NB, et al. Long-term meditators self-induce  
32 high-amplitude gamma synchrony during mental practice. *Proceedings of the National  
33 Academy of Sciences of the United States of America* 2004;101:16369-73.  
34  
35

36  
37 34. Arefnasab Z, Ghanei M, Noorbala AA, et  
38 al. Effect of Mindfulness Based Stress Reduction on Quality of Life (SF-36)  
39 and Spirometry Parameters, in Chemically Pulmonary Injured Veterans. *Iran J Public  
40 Health* 2013 ;42:1026-33.  
41  
42

43  
44 35. Mularski RA, Munjas BA, Lorenz KA, et al. Randomized controlled  
45 trial of mindfulness-based therapy for dyspnea in chronic obstructive lung disease. *J  
46 Altern Complement Med* 2009;15:1083-90.  
47  
48

49  
50 36. Harrison SL1, Lee A2, Janaudis-Ferreira T2, et al. Mindfulness in people with a  
51 respiratory diagnosis: A systematic Review. *Patient Educ Couns* 2016 ;99:348-55  
52  
53

54  
55 37. Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for  
56  
57  
58  
59  
60

1  
2  
3  
4 systematic review and meta-analysis protocols (PRISMA-P) 2015:

5  
6 elaboration and explanation. *BMJ* 2015;350:g7647.

7  
8  
9 38. Global Strategy for the Diagnosis, Management and Prevention of  
10 COPD. Global Initiative for Chronic Obstructive Lung Disease: GOLD,

11  
12  
13 2016. [http://www. goldcopd. org](http://www.goldcopd.org)

14  
15  
16 39. Group of Chronic Obstructive Pulmonary Disease, Branch of  
17 Respiratory Diseases, and Chinese Medical Association,. Guidance  
18 of diagnosis and treatment of chronic obstructive pulmonary disease

19  
20  
21 (revised edition in 2007),”. *Chin J Tuberc Respir Dis* 2007;30::8–17.

22  
23  
24 40. Higgins JPT, Green S (editors). *Cochrane Handbook for Systematic Reviews of*  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration,  
2011. Available at:

<http://www.equator-network.org/reporting-guidelines/cochrane-handbook-for-systematic-reviews-of-interventions-version-5-1-0/>

41. Review Manager (RevMan) [Computer program]. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.

42. Furlan AD, Pennick V, Bombardier C, et al. 2009 Updated Method Guidelines for Systematic Reviews in the Cochrane Back Review Group. *Spine* 2009;34:1929-41.

43. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. *BMJ* 2003;327:557–60.

44. StataCorp. *Stata Statistical Software: Release 12*. College Station, TX: StataCorp LP, 2011.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only


1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Figure captions:**

**Figure 1** Flow diagram of studies identified

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



90x90mm (600 x 600 DPI)



## Appendix A

### Pubmed search strategy

- #1 randomized controlled trial[Publication Type]
- #2 Randomized Controlled Trials as Topic"[Majr]
- #3 random[Text Word]
- #4 RCT[Text Word]
- #5 controlled clinical trial[Publication Type]
- #6 Clinical Trials as Topic"[Majr]
- #7 Single-Blind Method"[Majr]
- #8 Double-Blind Method"[Majr]
- #9 single blind[Text Word]
- #10 double blind[Text Word]
- #11 placebo[Text Word]
- #12 allocation[Text Word]
- #13 random allocation[Text Word]
- #14 case study[Text Word]
- #15 qualitative study[Text Word]
- #16 #1OR#2 OR #3OR#4 OR#5 OR#6 OR #7OR #8OR#9 OR#10 OR #11OR#12  
OR #13 OR #14 OR #15
- #17 "Pulmonary Disease, Chronic Obstructive"[Majr]
- #18 Airflow Obstruction[Title/Abstract] AND chronic[Title/Abstract]
- #19 COAD[Title/Abstract]
- #20 COPD[Title/Abstract]
- #21 Chronic Airflow Obstruction[Title/Abstract]
- #22 Chronic Obstructive Airway Disease[Title/Abstract]
- #23 Chronic Obstructive Lung Disease[Title/Abstract]
- #24 Chronic Obstructive Pulmonary Disease[Title/Abstract]
- #25 #15OR #16OR #17OR#18 OR#19 OR#20 OR#21 OR#22
- #26 "Mindfulness"[Majr]
- #27 Mindfulness[Title/Abstract]

- 1  
2  
3  
4 #28 Mindfulness-based cognitive therapy[Title/Abstract]  
5  
6 #29 MBCT[Text Word]  
7  
8 #30 mindfulness-based stress reduction[Title/Abstract]  
9  
10 #31 MBSR[Text Word]  
11  
12 #32 "Meditation"[Majr]  
13  
14 #33 meditation[Title/Abstract]  
15  
16 #34 mindfulness meditation[Title/Abstract]  
17  
18 #35 acceptance[Title/Abstract] AND commitment therapy[Title/Abstract]  
19  
20 #36 dialectical behavior therapy[Title/Abstract]  
21  
22 #37 cognitive behavioral stress management[Title/Abstract]  
23  
24 #38 integrative body–mind training[Title/Abstract]  
25  
26 #39 mindfulness-related interventions[Title/Abstract]  
27  
28 #40 Vipassana[Title/Abstract]  
29  
30 #41 Zen[Title/Abstract]  
31  
32 #42 mantra meditation[Title/Abstract]  
33  
34 #43 compassion focused therapy[Title/Abstract]  
35  
36 #44 #24 OR#25 OR #26OR#27 OR#28 OR #29OR#30 OR #31OR #32OR#33 OR  
37 #34OR#35 OR#36 OR #37OR#38 OR #39OR #40OR #41 OR #42OR #43OR #44  
38  
39 #45 "Humans"[Majr]  
40  
41 #46 "Animals"[Majr]  
42  
43 #47 #42NOT#43  
44  
45 #48 #16 AND #25 AND #44 AND #47  
46  
47  
48  
49

### Embase search strategy

50  
51 #1 'randomization'/exp OR 'placebo'/exp OR 'placebo effect'/exp OR 'single blind  
52 procedure'/exp OR 'double blind procedure'/exp OR 'randomized controlled trial'/exp  
53 OR 'randomized controlled trial (topic)'/exp OR 'controlled clinical trial'/exp  
54 OR 'controlled clinical trial (topic)'/exp OR 'clinical trial'/exp OR 'clinical trial  
55 (topic)'/exp OR 'case study'/exp OR 'qualitative study'/exp  
56  
57  
58  
59  
60

#2 random\*:ab,ti OR allocation:ab,ti OR placebo:ab,ti OR single AND blind:ab,ti  
OR double AND blind:ab,ti OR rct:ab,ti OR clinical AND trial\*:ab,ti

#3 #1 OR #2

#4 'Chronic Airflow Obstruction':ab,ti OR 'Chronic Obstructive Airway Disease  
'ab,ti OR 'Chronic Obstructive Lung Disease ':ab,ti 'Chronic Obstructive Pulmonary  
Disease ':ab,ti OR 'COAD ':ab,ti OR 'COPD ':ab,ti

#5 'mindfulness':ab,ti OR 'mindfulness-based cognitive therapy ':ab,ti OR '  
MBCT ':ab,ti 'mindfulness-based stress reduction':ab,ti OR 'MBSR ':ab,ti  
OR 'meditation ':ab,ti OR 'mindfulness meditation':ab,ti OR 'acceptance commitment  
therapy':ab,ti OR 'dialectical behavior therapy':ab,ti 'cognitive behavioral stress  
management':ab,ti OR 'integrative body–mind training':ab,ti OR 'mindfulness-related  
interventions':ab,ti OR 'Vipassana':ab,ti OR 'Zen':ab,ti OR 'mantra meditation':ab,ti  
OR 'compassion focused therapy':ab,ti

#6 #3 AND #4 AND #5

### **The Cochrane Library search strategy**

#1 "random\*" or allocation or "random allocation" or placebo or single blind or  
double blind or "randomized controlled trial\*" or RCT or "clinical trial \*" or "case  
stud\*" or "qualitative stud\*"

#2 randomized controlled trial:pt or clinical trial:pt

#3 #1 or #2

#4 Chronic Airflow Obstruction:ti,ab,kw or Chronic Obstructive Airway  
Disease:ti,ab,kw or Chronic Obstructive Lung Disease:ti,ab,kw or Chronic  
Obstructive Pulmonary Disease:ti,ab,kw or COAD:ti,ab,kw or COPD:ti,ab,kw

#5 mindfulness:ti,ab,kw or mindfulness-based cognitive therapy:ti,ab,kw or  
MBCT:ti,ab,kw or mindfulness-based stress reduction:ti,ab,kw or MBSR:ti,ab,kw or  
meditation:ti,ab,kw or mindfulness meditation:ti,ab,kw or acceptance commitment  
therapy:ti,ab,kw or dialectical behavior therapy:ti,ab,kw or cognitive behavioral stress  
management:ti,ab,kw or integrative body–mind training:ti,ab,kw or

mindfulness-related interventions:ti,ab,kw or Vipassana:ti,ab,kw or Zen:ti,ab,kw or  
mantra meditation:ti,ab,kw or 'compassion focused therapy:ti,ab,kw

#6 #3 and #4 and #5

### Web of science search strategy

#1 TS=("random \*" OR allocation OR "random allocation" OR placebo OR single  
blind OR single blind method OR double blind OR double blind method OR  
"randomized controlled trial\*" OR "randomized controlled trial\*" OR "RCT" OR  
"clinical trial \*"OR "case stud\*" OR "qualitative stud\*")

#2 TS=( Chronic Airflow Obstruction OR Chronic Obstructive Airway Disease OR  
Chronic Obstructive Lung Disease OR Chronic Obstructive Pulmonary Disease OR  
COAD OR COPD )

#3 TS=( mindfulness OR mindfulness-based cognitive therapy OR MBCT OR  
mindfulness-based stress reduction OR MBSR OR meditation OR mindfulness  
meditation OR acceptance commitment therapy OR dialectical behavior therapy OR  
cognitive behavioral stress management OR integrative body–mind training OR  
mindfulness-related interventions OR Vipassana OR Zen OR mantra meditation OR  
compassion focused therapy)

#4 #3 AND #2 AND #1

### CNKI search strategy

(SU = '随机' OR SU = '随机分配' OR SU = '随机对照' OR SU = '对照' OR SU = '盲法' OR SU = '单盲'  
OR SU = '双盲' OR SU = '随机对照实验' OR SU = '随机对照研究' OR SU = 'RCT' OR SU = '临床试  
验' OR SU = '临床研究' OR SU = '临床观察' OR SU = '临床试验' OR SU = '个案研究' OR SU = '质性  
研究') AND ( SU = '慢性阻塞性肺炎' OR SU = '慢性阻塞性肺部疾病' OR SU = 'COPD' OR SU =  
'COAD') AND ( SU = '正念' OR SU = '冥想' OR SU = '正念认知疗法' OR SU = ' MBCT' OR SU = '正  
念减压疗法' OR SU = 'MBSR' OR SU = '正念冥想' OR SU = '接受与承诺疗法' OR SU = '辩证行为  
疗法' OR SU = '认知行为压力管理' OR SU = '整合身心训练' OR SU = '内观' OR SU = '禅' OR SU =  
'曼陀罗禅修' OR SU = 同情聚焦治疗)

**CINAHL search strategy**

S1 MH("Random Assignment" OR "Placebos" OR "Placebo Effect" OR "Single-Blind" OR "Double-Blind" OR "Randomized Controlled Trial\*" OR "Clinical Trial\*" OR "Case Stud\*" OR "qualitative stud\*")

S2 TX(random OR allocation OR "random allocation" OR placebo OR single blind OR double blind OR "random controlled trial\*" OR RCT OR "Clinical Trial\*" OR "Case stud\*" OR "qualitative stud\*")

S3 S1 OR S2

S4 AB(Chronic Airflow Obstruction OR Chronic Obstructive Airway Disease OR Chronic Obstructive Lung Disease OR Chronic Obstructive Pulmonary Disease OR COAD OR COPD)

S5 AB(mindfulness OR mindfulness-based cognitive therapy OR MBCT OR mindfulness-based stress reduction OR MBSR OR meditation OR mindfulness meditation OR acceptance commitment therapy OR dialectical behavior therapy OR cognitive behavioral stress management OR integrative body–mind training OR mindfulness-related interventions OR Vipassana OR Zen OR mantra meditation OR compassion focused therapy)

S6 S3 AND S4 AND S5

**psychINFO search strategy**

1 ((doubl\* or singl\*) adj blind\*).mp.or ((random\* or clinical or control\*) adj (trial\* or study or studies)).mp.or ( clinical trial\* ).mp.or((case or qualitative) adj (study or studies)).mp.or( case stud\*).mp.or (qualitative stud\*).mp.

2 (Chronic Airflow Obstruction).mp.or(Chronic Obstructive Airway Disease).mp.or (Chronic Obstructive Lung Disease).mp.or(Chronic Obstructive Pulmonary Disease).mp.or (COAD ).mp.or(COPD).mp.

3 (mindfulness).mp.or(mindfulness-based cognitive therapy).mp.or (MBCT).mp.or(mindfulness-based stress reduction).mp.or (MBSR ).mp.or(meditation).mp.or (mindfulness meditation).mp.or(acceptance

1  
2  
3  
4 commitment therapy).mp.or (dialectical behavior therapy).mp.or(cognitive behavioral  
5 stress management).mp.or (integrative body–mind  
6 training ).mp.or(mindfulness-related interventions ).mp.or  
7 (Vipassana).mp.or(Zen).mp.or (mantra meditation ).mp.or(compassion focused  
8 therapy).mp.  
9  
10  
11  
12

13 4 1 and 2 and 3  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 checklist: recommended items to address in a systematic review protocol\***

Section and topic	Item No	Checklist item	Reported on page#
<b>ADMINISTRATIVE INFORMATION</b>			
Title:			
Identification	1a	Identify the report as a protocol of a systematic review	1
Update	1b	If the protocol is for an update of a previous systematic review, identify as such	
Registration	2	If registered, provide the name of the registry (such as PROSPERO) and registration number	2
Authors:			
Contact	3a	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author	1
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review	9
Amendments	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	N/A
Support:			
Sources	5a	Indicate sources of financial or other support for the review	9
Sponsor	5b	Provide name for the review funder and/or sponsor	9
Role of sponsor or funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol	9
<b>INTRODUCTION</b>			
Rationale	6	Describe the rationale for the review in the context of what is already known	3-6
Objectives	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	3-6
<b>METHODS</b>			

Eligibility criteria	8	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review	6-7
Information sources	9	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage	6-7
Search strategy	10	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated	15-20
Study records:			
Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review	7-8
Selection process	11b	State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)	7-8
Data collection process	11c	Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators	8
Data items	12	List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications	7
Outcomes and prioritization	13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale	7
Risk of bias in individual studies	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis	8
Data synthesis	15a	Describe criteria under which study data will be quantitatively synthesised	8
	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as $I^2$ , Kendall's $\tau$ )	8
	15c	Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression)	8-9
	15d	If quantitative synthesis is not appropriate, describe the type of summary planned	N/A



Meta-bias(es)	16	Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies)	9
Confidence in cumulative evidence	17	Describe how the strength of the body of evidence will be assessed (such as GRADE)	N/A

**\* It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0.**

*From: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015 Jan 2;349(jan02 1):g7647.*

# BMJ Open

## The Efficacy of Mindfulness-Based Interventions for COPD Patients: A systematic review and meta-analysis protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-026061.R2
Article Type:	Protocol
Date Submitted by the Author:	23-Feb-2019
Complete List of Authors:	<p>tian, lingyun; Central South University, Xiangya Nursing School; Anhui University of Chinese Medicine, School of Nursing</p> <p>zhang, ying; Central South University, Department of infection control , Xiangya hospital</p> <p>li, li; Central South University, Department of nursing, Xiangya hospital</p> <p>wu, ying; Central South University, Department of burn, Xiangya hospital</p> <p>Li, Ying-lan; Central South University, Department of nursing, Xiangya hospital</p>
<b>Primary Subject Heading</b>:	Evidence based practice
Secondary Subject Heading:	Respiratory medicine
Keywords:	MEDICAL EDUCATION & TRAINING, Chronic airways disease < THORACIC MEDICINE, Protocols & guidelines < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Quality in health care < HEALTH SERVICES ADMINISTRATION & MANAGEMENT

SCHOLARONE™  
Manuscripts

1  
2  
3  
4 **The Efficacy of Mindfulness-Based Interventions for COPD Patients: A**  
5 **systematic review and meta-analysis protocol**  
6  
7

8 Lingyun Tian<sup>1, 2</sup>, Ying Zhang<sup>3</sup>, Li Li<sup>4</sup>, Ying Wu<sup>5</sup>, Yinglan Li<sup>4</sup>  
9

10 1 Xiangya Nursing School, Central South University, Changsha, China  
11

12  
13 2 School of Nursing, Anhui University of Chinese Medicine, Hefei, China  
14

15  
16 3 Department of infection control , Xiangya hospital, Central South University,  
17 Changsha, China  
18

19  
20  
21 4 Department of nursing, Xiangya hospital, Central South University, Changsha,  
22 China  
23

24  
25  
26 5 Department of burn, Xiangya hospital, Central South University, Changsha, China  
27  
28  
29  
30

31 **Email:**  
32

33  
34 Lingyun Tian: tianlingyun@csu.edu.cn  
35

36  
37 Ying Zhang: 350208667@qq.com  
38

39  
40 Li Li: 468053702@qq.com  
41

42  
43 Ying Wu: wuying2341@126.com  
44

45  
46 Yinglan Li: yuyan0202@sina.com  
47

48 **correspondence to professor Yinglan Li**  
49

50  
51 **Address:** 87 Xiang Ya Road Changsha 410008 Hunan, China  
52  
53

54 **Word count:** 4046  
55  
56  
57  
58  
59  
60

## ABSTRACT

**Introduction** Chronic obstructive pulmonary disease (COPD) is a common chronic respiratory disease. It has adverse effects on patients' physical health, mental well-being and life quality. The purpose of mindfulness-based interventions (MBIs) is to raise non-judgemental awareness and attention to the current internal and external experience. Namely the attention is shifted from the perceived and involuntary inner activities to current experience, keeping more curious, open and accepting attitudes towards current experience. Although some studies on the intervention effect of MBIs in COPD patients have been conducted, whose results are controversial, especially on the dyspnea, the level of mindfulness and life quality. Therefore, the systematic review of MBIs in COPD patients is required to provide the available evidence for the further study.

**Methods and analysis** In this study, different studies from various databases will be involved. Randomized controlled trials (RCTs)/quantitative studies, qualitative studies and case studies on the effect of MBIs in COPD patients aged over 18 will be included. We will search the literature in the databases of PubMed, Embase, Web of Science, CINAHL, the Cochrane Library, PsycINFO and China National Knowledge

1  
2  
3  
4 Infrastructure (CNKI). The primary outcomes will include the MBIs efficacy for  
5 COPD patients in terms of the dyspnea, depression and anxiety. The secondary  
6 outcomes will include that in terms of life quality, mindful awareness, 6-minute walk  
7 test and nutritional risk index. Data extraction will be conducted by two researchers  
8 independently, and bias risk of the meta-analysis will be evaluated based on the  
9 Cochrane Handbook of Systematic Reviews of Interventions. All data analysis will be  
10 conducted by data statistics software of Review Manager 5.3. and Stata12.0.  
11  
12  
13  
14  
15  
16  
17

18 **Ethics and dissemination** The examination and agreement of the ethics committee  
19 are not required in this study. We intend to publish the study results in a journal or  
20 conference presentations.  
21  
22  
23  
24

25 **PROSPERO registration number** CRD42018102323  
26  
27  
28  
29  
30  
31  
32

### 33 **Strengths and limitations of this study**

- 34 ● This study provides a detailed and evidence-based study on the efficacy of MBIs  
35 in COPD patients.
- 36 ● Extensive search strategies and inclusion criteria will be included in this study,  
37 indicating a comprehensive narrative of the available evidence.
- 38 ● Data extraction and bias risk of studies involved in the meta-analysis will be  
39 independently conducted.
- 40 ● Sensitivity and subgroup analysis will be used to explore the source of  
41 heterogeneity for the meta-analysis, and the potential publication bias will be  
42 assessed by the funnel plot combined with Egger's regression tests.
- 43 ● Although detailed retrieval strategies have been formulated in our study,  
44 unpublished trials may not be included.
- 45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## INTRODUCTION

As a common disease, chronic obstructive pulmonary disease (COPD) is characterized by persistent and progressive airflow limitation, accompanied by an increase in chronic inflammatory responses caused by harmful particles or gases in the airway and lungs. Besides, the acute exacerbation and comorbidities affect the overall severity of this disease.<sup>1</sup> Due to the high mortality, COPD endangers patients' health and lives, placing a heavy financial burden on their families and society.<sup>2</sup>

It is reported that the incidence of COPD is about 10% in the worldwide.<sup>3</sup> COPD might jump from the fourth to the third cause of the global death by 2020, ranking the fifth in the global economic burden.<sup>4</sup> An epidemiological survey of COPD in China shows that the prevalence rate of COPD is 8.2% for people older than 40 years old, the number of death and disabled caused by COPD are more than 1 million and 5~10 million a year.<sup>5</sup> In rural areas, the mortality rate of respiratory diseases ranks first among all causes of death in China.<sup>6</sup>

COPD has a serious impact on patients' physical health, mental well-being and life quality. General adverse physiological effects are mainly manifested in skeletal muscle consumption (SMW) and dysfunction (SMD), weight loss, cardiovascular complications, malnutrition and body composition change.<sup>7-9</sup> With the decreased amount of activity, the muscle strength and resistance of the patient's body are gradually weakened, and the symptom of dyspnea becomes more serious. Thus, a vicious cycle is formed, namely from the breathing difficulty to activity reduction to the dyspnea aggravation, finally resulting in accelerated deterioration of physical condition.<sup>10 11</sup> Besides, mood disorders are common symptoms among COPD patients. In recent years, studies have confirmed that anxiety and depression are the most common and most easily overlooked complications in COPD patients.<sup>12-14</sup> Anxiety and depression can discourage patients in their lives, reduce their confidence in medical aspirations and treatment compliance, in turn the number of acute

1  
2  
3  
4 exacerbations, hospitalization frequency and time are increased with greater disability  
5 and dyspnoea.<sup>15 16</sup> Life quality is a key indicator for estimating the disease burden,  
6 especially for chronic diseases.<sup>17</sup> Research has indicated that COPD patients may  
7 have a poor life quality.<sup>17 18</sup> Depressive symptoms negatively influence their mental  
8 life quality, and dyspnea often interferes with their health-related life quality.<sup>18 19</sup>  
9  
10  
11  
12  
13

14 Mindfulness-based interventions (MBIs) are usually referred to short interventions  
15 (generally eight courses) provided in a group environment, including mindfulness  
16 meditation exercises and principles.<sup>20</sup> The purpose of MBIs is to raise  
17 non-judgemental awareness and attention to the current internal and external  
18 experience. Namely the attention is shifted from the perceived and involuntary inner  
19 activities to current experience, keeping more curious, open and accepting attitudes  
20 toward current experience.<sup>21-23</sup> Present mindfulness interventions include  
21 mindfulness-based cognitive therapy (MBCT), mindfulness-based stress reduction  
22 (MBSR), and brief mindfulness meditation training intervention.<sup>24</sup> There are also  
23 other MBIs which include mindfulness training exercises as a part of treatment  
24 program, such as the acceptance and commitment therapy, compassion focused  
25 therapy, dialectical behavior therapy, integrative body-mind training and cognitive  
26 behavioral stress management.<sup>24 25</sup> These methods have been proved to be beneficial to  
27 patients.<sup>24 25</sup>  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41

42 It is proved that mindfulness interventions can reduce symptoms of chronic disease  
43 and improve accurate symptom assessment, which may improve disease management  
44 and well-being in patients with COPD.<sup>26</sup> The following themes are proposed in the  
45 qualitative evidence on MBCT positive effect of anxious and depressed asthma and  
46 COPD patients: combining lung rehabilitation advice with mindfulness; greater  
47 acceptance and reduction of disease-related stigma; developing a new relationship  
48 between breathing, activity and related thoughts; noticing subtle physical sensations  
49 and early signs of difficulty breathing; being creative with limitations and removing  
50 mental barriers to become more active; having a stronger sense of control.<sup>27</sup>  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 It is verified that mindfulness interventions are effective in improving the mindful  
5 awareness, CD3<sup>+</sup> T cell number, CD4<sup>+</sup> T cell number<sup>28</sup> and depression in COPD,<sup>29</sup>  
6 reducing the nutritional risk index and CD8<sup>+</sup> T cell number.<sup>28</sup> Systematic health  
7 education combined mindfulness interventions can lower the dyspnea and the  
8 nutritional risk index, improve the mindful awareness, compared with the only used  
9 systematic health education intervention.<sup>30</sup> A 10-minute mindfulness intervention in  
10 COPD patients has shown that there is a changing tendency in outcomes of the  
11 intervention group, including depression, anxiety, happiness, dyspnoea, mindfulness  
12 and stress. While no significant difference exists among groups, most participants  
13 supposed that the mindfulness interventions are useful and they are glad to  
14 recommend it.<sup>16</sup> It is concluded that meditation may improve the detection ability,  
15 monitor immediate ventilatory needs and respiratory load, improve the mental acuity,  
16 promote their active participation in daily life activities, and achieve better self-care  
17 management of disease for anxious COPD patients.<sup>31-33</sup> MBSR is verified to improve  
18 the life quality of veterans with chemical lung injury, but not their lung function.<sup>34</sup>  
19 However, compared with the support group, no significant improvement is observed  
20 in exacerbation rates of the RCT trial, health-related life quality measures,  
21 mindfulness, 6MWT distance, dyspnea, stress, or symptom scores for COPD patients  
22 after receiving the mindfulness-based breathing therapy.<sup>35</sup>

23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41 In 2016, a systematic review was conducted to examine the effect of mindfulness  
42 on mindful awareness, health-related life quality and stress in adults with respiratory  
43 illnesses. In this meta-analysis, three studies propose that mindfulness cannot improve  
44 the health-related life quality, while other two studies claim that mindfulness can not  
45 improve the level of mindfulness and relieve stress. Different conclusions are largely  
46 caused by the inconsistent research methodologies.<sup>36</sup> In the former study of adult  
47 respiratory diagnosis published in 2016, three outcomes were obtained for the MBSR  
48 intervention. In this paper, COPD patients with different types of MBIs and more  
49 outcomes are investigated. Considering the small number of eligible studies, we  
50 intended to involve RCTs/quantitative studies, qualitative studies and case studies in  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3  
4 this study to describe the application status of MBIs in COPD patients. Besides,  
5 meta-analysis should be only performed on the basis of RCTs.  
6  
7

8 The updated systematic review and meta-analysis is performed for two  
9 objectives:(1) describe the application status of MBIs delivered for COPD patients  
10 and (2) examine the effect of MBIs on outcomes including depression, anxiety, life  
11 quality, mindful awareness, 6-minute walk test and nutritional risk index.  
12  
13  
14  
15

## 16 17 **METHODS AND ANALYSIS**

### 18 19 **Study registration**

20 This systematic review and meta-analysis protocol have been registered in the  
21 PROSPERO. The protocol is strictly reported by the requirements of Preferred  
22 Reporting Items for Systematic Reviews and Meta-Analysis Protocols (PRISMA-P).<sup>37</sup>  
23  
24  
25  
26  
27  
28

### 29 **Inclusion criteria for study selection**

#### 30 31 **Types of included studies**

32 We intend to perform quantitative studies, qualitative studies and case studies in this  
33 systematic review to describe the application status of MBIs in COPD patients. And  
34 all RCTs evaluating the efficacy of MBIs in COPD patients will also be included in  
35 this study. No restrictions on the language and time of publication. Animal  
36 mechanism studies, RCT protocol and duplicate publication will be excluded. It  
37 should be noted that duplicate publication refers to an article substantially overlaps  
38 with another published one in printing or electronic media.<sup>38</sup>  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48

#### 49 **Participants**

50 Patients aged at least 18 years old with a clinical diagnosis of COPD confirmed by  
51 postbronchodilator forced expiratory volume in 1 second (FEV<sub>1</sub>) <80% of the  
52 predicted value in combination with an FEV<sub>1</sub>/forced vital capacity <70% in  
53 accordance with the global initiative for COPD,<sup>39</sup> the American Thoracic Society, the  
54 British Thoracic Society, the European Respiratory Society or Chinese COPD  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 guideline<sup>40</sup> will be included.  
5

## 6 **Intervention**

7  
8  
9 The study aims at the efficacy of MBIs in COPD patients. Thus, different types of  
10 MBIs should be covered, including MBSR, MBCT, acceptance and commitment  
11 therapy, brief mindfulness meditation training interventions, cognitive behavioral  
12 stress management, dialectical behavior therapy, integrative body-mind training and  
13 compassion focused therapy etc. The intervention measures taken by the experimental  
14 group must be MBIs or MBIs with other combined treatment methods. The treatment  
15 of control group must be the only therapy as usual or active comparison interventions,  
16 or combined with other treatment methods.  
17  
18  
19  
20  
21  
22  
23  
24

## 25 **Outcome measures**

26  
27  
28 The primary outcomes will include the MBIs efficacy for COPD patients in terms of  
29 the dyspnea based on the scale, such as the modified Medical Research Council  
30 (mMRC) scale<sup>30</sup> and the Borg Dyspnea Scale,<sup>35</sup> depression and anxiety evaluated by  
31 the scale, such as the Hospital Anxiety and Depression Scale(HADS).<sup>16</sup> The  
32 secondary outcomes will include that the evaluation of life quality (based on SF-36  
33 questionnaire<sup>34</sup> and the Saint George Respiratory Questionnaire (SGRQ)<sup>35</sup>), mindful  
34 awareness (based on the Philadelphia Mindfulness Scale<sup>16</sup> and the 5-Factor  
35 Mindfulness Questionnaire<sup>35</sup>), 6-minute walk test (based on the Borg Dyspnea  
36 Scale<sup>35</sup>) and nutritional risk index (based on the nutritional risk screening 2002  
37 (NRS2002) scale<sup>28 30</sup>).  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

## 48 **Search strategy**

49  
50  
51 We intend to retrieve the literature search from PubMed, Web of Science, Embase,  
52 the Cochrane Library, CINAHL, PsycINFO, and CNKI in accordance with database  
53 rules. During the literature retrieval, information expert and lung disease expert have  
54 offered the help and guidance. To fully retrieve the eligible studies, a comprehensive  
55 retrieval strategy will be adopted, combining with MeSH terms, text word, title/abstract  
56  
57  
58  
59  
60

1  
2  
3  
4 and synonyms. These detailed search strategies for different databases are shown in  
5  
6 Appendix A.

## 8 **Data collection and analysis**

### 10 **Studies selection**

11  
12  
13 The selection of research literature will be independently carried out by two  
14  
15 researchers. Firstly, we will make a preliminary selection by reading the abstract and  
16  
17 title. Secondly, we will download all relevant studies for the further selection  
18  
19 according to the inclusion criteria. If there is a different opinion between two  
20  
21 researchers, the issue will be discussed to reach an agreement. If it fails to reach a  
22  
23 consensus through discussion, the third researcher will make the final decisions. The  
24  
25 selection process is displayed in the PRISMA flowchart (Fig. 1).

### 27 **Data extraction**

28  
29  
30 We will explore the characteristics of different studies qualitatively. Data extraction  
31  
32 will be dependently conducted by two researchers, including the publication time,  
33  
34 authors, region, participants (n, gender and age), study design, intervention methods,  
35  
36 intervention duration, outcomes, assessment method, significant findings and duration  
37  
38 of follow-up. If two researchers have different opinions and cannot to reach a  
39  
40 consensus through discussion, the third researcher will make final decisions.

### 42 **Bias risk assessment**

43  
44  
45 To evaluate bias risk in the meta-analysis, all studies involved in the meta-analysis  
46  
47 will be evaluated based on the Cochrane Handbook of Systematic Reviews of  
48  
49 Interventions.<sup>41</sup> Assessment items will involve the random sequence generation,  
50  
51 allocation concealment, blinding of participants and personnel, blinding of outcome  
52  
53 assessment, incomplete outcome data, selective reporting and other bias. If there are  
54  
55 different opinions, the third researcher will make the final decision.

### 57 **Statistical analysis**

1  
2  
3  
4 We will conduct data analysis by data statistics software of Review Manager 5.3. and  
5 Stata12.0. The continuous variables will be analyzed by the mean difference (MD) or  
6 standardized mean difference (SMD) with 95% confidence intervals (CIs), and  
7 classified variables will be analyzed by the risk ratio(RR) or the odd ratio(OR) with  
8 95% confidence intervals (CIs). When extracting raw data from studies, we will  
9 estimate RR in longitudinal, cohort and cross-sectional studies and OR in case-control  
10 studies.<sup>42</sup> We will use the random effects model to conduct the meta-analysis based on  
11 research recommendations.<sup>43</sup> Heterogeneity will be calculated based on the  $X^2$  test,  
12 and the judgement of heterogeneity degree will be depended on the  $I^2$  value( $I^2 >50\%$   
13 or not) or  $P$ -value( $P < 0.10$  or not).<sup>44</sup> We will use sensitivity and subgroup analysis to  
14 explore the source of heterogeneity. The following subgroup analysis will be  
15 performed on different types of MBIs (e.g. MBSR, MBCT, acceptance commitment  
16 therapy, meditation, dialectical behavior therapy and cognitive behavioral stress  
17 management etc), types of patients, intervention duration and duration of follow-up.  
18 The potential publication bias of all used studies in the meta-analysis will be assessed  
19 by funnel plot combined with Egger's regression test.<sup>45</sup>

### 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 **Patient and public involvement**

37  
38 We currently collect data from previously published studies in this study protocol of a  
39 meta-analysis, hence no patients and the general public have been involved in.

### 40 41 42 43 **DISCUSSION**

44  
45 This study aims to systematically review the efficacy of MBIs in COPD patients. It  
46 will provide a detailed and evidence-based overview of the effect of MBIs on  
47 improving COPD patients' dyspnea, depression, anxiety, life quality, mindful  
48 awareness, 6-minute walk test and nutritional risk index. This result will provide an  
49 evidence-based basis for clinical practitioners in selecting mindfulness-based  
50 therapies for COPD patients, and offer patients with appropriate personalized  
51 interventions.  
52  
53  
54  
55  
56  
57  
58  
59  
60

## ETHICS AND DISSEMINATION

Since this study is a systematic review, the findings are based on the published evidence. Therefore, the examination and agreement of the ethics committee are not required in this study. We intend to publish the study results in a journal or conference presentations.

**Contributors** T-LY is responsible for the writing of the entire manuscript. The electronic database retrieval strategy is formulated by T-LY and ZY. LL and WY will independently screen the research, extract the needed research data and assess the bias risk. If LL and WY fail to reach an agreement in the above process, the final decision will be made by L -YL. The statistical analysis will be performed by T-LY.

**Funding** This work is supported by Hunan provincial development and reform commission (the Project Grant No. [2016]65) and Hunan Provincial Social Science Foundation (the Project Grant No.14YBA404)

**Competing interests** None declared.

**Patient consent** It is not required in this systematic review protocol.

## REFERENCE

- 1.Cheng Y, Han X, Luo Y, *et al.* Analysis of co-morbidities of chronic obstructive pulmonary disease for patients in Yangpu District of Shanghai. *Journal of Shanghai Jiao Tong University Medical Science* 2015;35:82-5,96.
2. Liu W, Ge ZX, Li B. Study on traditional Chinese medicine constitution types of patients with Acute Exacerbation of COPD ( AECOPD) with secondary pulmonary fungal infections and prevention and treatment. *Chinese Journal of Experimental Traditional Medical Formulae* 2013;19:321-4.
3. HURD, Suzanne S, LENFANT, *et al.* Chronic obstructive pulmonary disease in five latin American cities (the PLATINO study) : a prevalence study. Commentary. *Lancet* 2005;366:1875-81.

- 1  
2  
3  
4 4. Murray CJ, Lopez AD, Mathers CD, *et al.* The Global Burden of Disease 2000  
5 project: aims, methods and data sources (GPE Discussion Paper No. 36). 2001.  
6  
7
- 8  
9 5. Zhong NS, Chen W, Yao WZ, *et al.* Prevalence of chronic obstructive pulmonary  
10 disease in China: a large, population-based survey. *Am J Respir Crit Care Med*  
11  
12 2007;176:753-60.  
13  
14
- 15  
16 6. Qian GS. Efforts on improving the diagnosis and treatment of respiratory diseases in  
17 China. *Chinese Journal of lung disease (Electronic Version)* 2015;5:1-3.  
18  
19
- 20  
21 7. Pitta F, Troosters T, Spruit MA, *et al.* Characteristics of physical activities in daily  
22 life in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*  
23 2005;171:972-7.  
24  
25
- 26  
27 8. Shrikrishna D, Patel M, Tanner RJ, *et al.* Quadriceps wasting and physical inactivity  
28 in patients with COPD. *Eur Respir J* 2012; 40:1115-22.  
29  
30
- 31  
32 9. Osthoff AK, Taeymans J, Kool J, *et al.* Association between peripheral muscle  
33 strength and daily physical activity in patients with COPD: a systematic literature  
34 review and meta-analysis. *J Cardiopulm Rehabil Prev* 2013; 33:351-9.  
35  
36
- 37  
38 10. Reardon JZ, Lareau SC, Zuwallack R. Functional status and quality of life in  
39 chronic obstructive pulmonary disease. *Am J Med* 2006;119:32-7.  
40  
41
- 42  
43 11. Zuwallack R. How are you doing? What are you doing? Differing perspectives in  
44 the assessment of individuals with COPD. *COPD* 2007; 4:293-7.  
45  
46
- 47  
48 12. Li JX, Qiu XM, Wu CW. Correlation between BODE index of patients with  
49 chronic obstructive pulmonary disease and anxiety depression symptoms. *Journal of*  
50 *Clinical Pulmonary Medicine* 2016;21:460-3  
51  
52
- 53  
54 13. Maurer J, Rebbapragada V, Borson S, *et al.* Anxiety and depression in COPD:  
55 current understanding, unanswered questions, and research needs. *Chest*  
56 2008;134:43S.  
57  
58  
59  
60

- 1  
2  
3  
4 14. Norwood R. Prevalence and impact of depression in chronic obstructive  
5 pulmonary disease patients. *Curr Opin Pulm Med* 2006;12:113-7.  
6  
7  
8 15. Laurin C, Moullec G, Bacon SL, *et al.* Impact of anxiety and depression on  
9 chronic obstructive pulmonary disease exacerbation risk. *Am J Respir Crit Care Med*  
10 2012;185:918-23.  
11  
12  
13 16. Perkins-Porras L, Riaz M, Okekunle A, *et al.* Feasibility study to assess the effect  
14 of a brief mindfulness intervention for patients with chronic obstructive pulmonary  
15 disease: a randomized controlled trial. *Chron Respir Dis* 2018;15:400-10  
16  
17  
18 17. Pengpid S, Peltzer K. The Impact of Chronic Diseases on the quality of life of  
19 primary care patients in Cambodia, Myanmar and Vietnam. *Iran J Public Health*  
20 2018; 47:1308-16.  
21  
22  
23 18. Ivziku D, Clari M, Piredda M, *et al.* Anxiety, depression and quality of life in  
24 chronic obstructive pulmonary disease patients and caregivers: an actor-partner  
25 interdependence model analysis. *Qual Life Res* 2018. doi:  
26 10.1007/s11136-018-2024-z. [Epub ahead of print]  
27  
28  
29 19. Ries AL. Impact of chronic obstructive pulmonary disease on quality of life: the  
30 role of dyspnea. *Am J Med* 2006 ;119:12-20.  
31  
32  
33 20. Strauss C, Cavanagh K, Oliver A, *et al.* Mindfulness-based interventions for  
34 people diagnosed with a current episode of an anxiety or depressive disorder: a  
35 meta-analysis of randomised controlled trials. *Plos One* 2014;9:e96110.  
36  
37  
38 21. Brown KW, Ryan RM. The benefits of being present: mindfulness and its role in  
39 psychological well-being. *J Pers Soc Psychol* 2003;84:822-48.  
40  
41  
42 22. Williams JM, Teasdale JD, Segal ZV, *et al.* Mindfulness-based cognitive therapy  
43 reduces overgeneral autobiographical memory in formerly depressed patients. *J*  
44 *Abnorm Psychol* 2000;109:150-5.  
45  
46  
47 23. Bishop SR, Lau M, Shapiro S, *et al.* Mindfulness: A proposed operational  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3  
4 definition. *Clinical Psychology: Science and Practice* 2010;11:230-41.  
5  
6  
7 24.Creswell J D. Mindfulness Interventions. *Annu Rev Psycho* 2016;68:491-516.  
8  
9  
10 25.Craig C, Hiskey S, Royan L, *et al.* Compassion focused therapy for people with  
11 dementia: A feasibility study. *Int J Geriatr Psychiatry*. 2018. doi: 10.1002/gps.4977.  
12 [Epub ahead of print]  
13  
14  
15 26.Chan RR, Giardino N, Larson JL.A pilot  
16  
17 study:mindfulness meditation intervention in COPD. *Int J Chron Obstruct Pulmon Dis*  
18 2015;10:445-54.  
19  
20  
21  
22 27.Malpass A, Kessler D, Sharp D, *et al.* MBCT for patients with respiratory  
23 conditions who experience anxiety and depression: A qualitative study. *Mindfulness*  
24 2015; 6:1-11.  
25  
26  
27 28.Li JN,Guo X,Wang HY.Application of mindfulness intervention in health  
28  
29 wducation on patients with pulmonary tuberculosis complicated with COPD. *Chinese*  
30 *Nursing Research* 2015;29:2983-6.  
31  
32  
33  
34 29.Panagioti M, Scott C, Blakemore A, *et al.* Overview of the prevalence, impact, and  
35 management of depression and anxiety in chronic obstructive pulmonary disease. *Int J*  
36 *Chron Obstruct Pulmon Dis* 2014;9:1289-306.  
37  
38  
39  
40  
41 30.Wang DM.Effect of systematic health education combined with mindful behavior  
42 nursing intervention on patients with tuberculosis combined with COPD. *Laboratory*  
43 *Medicine and Clinic* 2017;14:1819-21.  
44  
45  
46  
47 31.Kim YY, Choi JM, Kim SY, *et al.* Changes in EEG of children during brain  
48 respiration-training. *Am J Chin Med* 2002;30:405-17.  
49  
50  
51  
52 32.Chan AS, Han YMY, Cheung MC. Electroencephalographic (EEG) measurements  
53 of mindfulness-based triarchic body-pathway relaxation technique: A pilot study.  
54 *Appl Psychophysiol Biofeedback* 2008;33:39-47.  
55  
56  
57  
58 33.Lutz A, Greischar LL, Rawlings NB, *et al.* Long-term meditators self-induce  
59  
60



1  
2  
3  
4 high-amplitude gamma synchrony during mental practice.*Proc Natl Acad Sci U S A*  
5 2004;101:16369-73.  
6

7  
8 34.Arefnasab Z, Ghanei M, Noorbala AA, *et al.* Effect of mindfulness based stress  
9 reduction on quality of life (SF-36) and spirometry parameters, in chemically  
10 pulmonary injured Veterans. *Iran J Public Health* 2013 ;42:1026-33.  
11  
12

13  
14 35.Mularski RA, Munjas BA, Lorenz KA, *et al.*Randomized controlled trial of  
15 mindfulness-based therapy for dyspnea in chronic obstructive lung disease.*J Altern*  
16 *Complement Med* 2009;15:1083-90.  
17  
18

19  
20 36.Harrison SL, Lee A, Janaudis-Ferreira T,*et al.*Mindfulness in people with a  
21 respiratory diagnosis: A systematic Review.*Patient Educ Couns* 2016 ;99:348-55.  
22  
23

24  
25 37.Shamseer L, Moher D, Clarke M, *et al.* Preferred reporting items for  
26 systematic review and meta-analysis protocols (PRISMA-P) 2015:  
27 elaboration and explanation. *BMJ* 2015;350:g7647.  
28  
29  
30

31  
32 38. Whan-Seok Choi, Sang-Wook Song, Sun-Myeong Ock,*et al.*Duplicate publication  
33 of articles used in meta-analysis in Korea.*Springerplus* 2014; 3: 182-7.  
34  
35

36  
37 39.Global Strategy for the Diagnosis, Management and prevention of  
38 COPD. Global Initiative for Chronic Obstructive Lung Disease: GOLD,  
39 2016. [http://www. goldcopd. org](http://www.goldcopd.org)  
40  
41  
42  
43  
44

45  
46 40.Group of Chronic Obstructive Pulmonary Disease, Branch of  
47 Respiratory Diseases, and Chinese Medical Association. Guidance  
48 of diagnosis and treatment of chronic obstructive pulmonary disease  
49 (reversed edition in 2007). *Chin J Tuberc Respir Dis* 2007;30:8–17.  
50  
51  
52  
53  
54

55  
56 41. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of  
57 Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration,  
58  
59  
60

1  
2  
3  
4 2011. Available at:

5 <http://www.equator-network.org/reporting-guidelines/cochrane-handbook-for-systematic-reviews-of-interventions-version-5-1-0/>  
6  
7  
8

9  
10 42. Evangelia Simou, John Britton, Jo Leonardi-Bee. Alcohol and the risk of  
11 pneumonia: a systematic review and meta-analysis. *BMJ Open*. 2018; 8(8): e022344.  
12  
13

14  
15 43. Furlan AD, Pennick V, Bombardier C, *et al*. 2009 Updated method guidelines for  
16 systematic reviews in the cochrane back review group. *Spine* 2009;34:1929-41.  
17  
18

19  
20 44. Higgins JP, Thompson SG, Deeks JJ, *et al*. Measuring inconsistency in  
21 meta-analyses. *BMJ* 2003;327:557-60.  
22  
23

24  
25 45. StataCorp. Stata Statistical Software: Release 12. College Station, TX: StataCorp  
26 LP, 2011.  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60


1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Figure captions:**

**Figure 1** Flow diagram of studies identified

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



90x90mm (600 x 600 DPI)

## Appendix A

### Pubmed search strategy

- #1 randomized controlled trial[Publication Type]
- #2 Randomized Controlled Trials as Topic"[Majr]
- #3 random[Text Word]
- #4 RCT[Text Word]
- #5 controlled clinical trial[Publication Type]
- #6 Clinical Trials as Topic"[Majr]
- #7 Single-Blind Method"[Majr]
- #8 Double-Blind Method"[Majr]
- #9 single blind[Text Word]
- #10 double blind[Text Word]
- #11 placebo[Text Word]
- #12 allocation[Text Word]
- #13 random allocation[Text Word]
- #14 case study[Text Word]
- #15 qualitative study[Text Word]
- #16 #1OR#2 OR #3OR#4 OR#5 OR#6 OR #7OR #8OR#9 OR#10 OR #11OR#12  
OR #13 OR #14 OR #15
- #17 "Pulmonary Disease, Chronic Obstructive"[Majr]
- #18 Airflow Obstruction[Title/Abstract] AND chronic[Title/Abstract]
- #19 COAD[Title/Abstract]
- #20 COPD[Title/Abstract]
- #21 Chronic Airflow Obstruction[Title/Abstract]
- #22 Chronic Obstructive Airway Disease[Title/Abstract]
- #23 Chronic Obstructive Lung Disease[Title/Abstract]
- #24 Chronic Obstructive Pulmonary Disease[Title/Abstract]
- #25 #15OR #16OR #17OR#18 OR#19 OR#20 OR#21 OR#22
- #26 "Mindfulness"[Majr]
- #27 Mindfulness[Title/Abstract]

- 1  
2  
3  
4 #28 Mindfulness-based cognitive therapy[Title/Abstract]  
5  
6 #29 MBCT[Text Word]  
7  
8 #30 mindfulness-based stress reduction[Title/Abstract]  
9  
10 #31 MBSR[Text Word]  
11  
12 #32 "Meditation"[Majr]  
13  
14 #33 meditation[Title/Abstract]  
15  
16 #34 mindfulness meditation[Title/Abstract]  
17  
18 #35 acceptance[Title/Abstract] AND commitment therapy[Title/Abstract]  
19  
20 #36 dialectical behavior therapy[Title/Abstract]  
21  
22 #37 cognitive behavioral stress management[Title/Abstract]  
23  
24 #38 integrative body–mind training[Title/Abstract]  
25  
26 #39 mindfulness-related interventions[Title/Abstract]  
27  
28 #40 Vipassana[Title/Abstract]  
29  
30 #41 Zen[Title/Abstract]  
31  
32 #42 mantra meditation[Title/Abstract]  
33  
34 #43 compassion focused therapy[Title/Abstract]  
35  
36 #44 #24 OR#25 OR #26OR#27 OR#28 OR #29OR#30 OR #31OR #32OR#33 OR  
37 #34OR#35 OR#36 OR #37OR#38 OR #39OR #40OR #41 OR #42OR #43OR #44  
38  
39 #45 "Humans"[Majr]  
40  
41 #46 "Animals"[Majr]  
42  
43 #47 #42NOT#43  
44  
45 #48 #16 AND #25 AND #44 AND #47  
46  
47  
48  
49

### Embase search strategy

50  
51 #1 'randomization'/exp OR 'placebo'/exp OR 'placebo effect'/exp OR 'single blind  
52 procedure'/exp OR 'double blind procedure'/exp OR 'randomized controlled trial'/exp  
53 OR 'randomized controlled trial (topic)'/exp OR 'controlled clinical trial'/exp  
54 OR 'controlled clinical trial (topic)'/exp OR 'clinical trial'/exp OR 'clinical trial  
55 (topic)'/exp OR 'case study'/exp OR 'qualitative study'/exp  
56  
57  
58  
59  
60

#2 random\*:ab,ti OR allocation:ab,ti OR placebo:ab,ti OR single AND blind:ab,ti  
OR double AND blind:ab,ti OR rct:ab,ti OR clinical AND trial\*:ab,ti

#3 #1 OR #2

#4 'Chronic Airflow Obstruction':ab,ti OR 'Chronic Obstructive Airway Disease  
' :ab,ti OR ' Chronic Obstructive Lung Disease ':ab,ti ' Chronic Obstructive Pulmonary  
Disease ':ab,ti OR ' COAD ':ab,ti OR ' COPD ':ab,ti

#5 'mindfulness':ab,ti OR 'mindfulness-based cognitive therapy ':ab,ti OR '  
MBCT ':ab,ti 'mindfulness-based stress reduction':ab,ti OR 'MBSR ':ab,ti  
OR 'meditation ':ab,ti OR 'mindfulness meditation':ab,ti OR 'acceptance commitment  
therapy':ab,ti OR ' dialectical behavior therapy':ab,ti 'cognitive behavioral stress  
management':ab,ti OR ' integrative body–mind training':ab,ti OR 'mindfulness-related  
interventions':ab,ti OR 'Vipassana':ab,ti OR 'Zen':ab,ti OR 'mantra meditation':ab,ti  
OR 'compassion focused therapy':ab,ti

#6 #3 AND #4 AND #5

### **The Cochrane Library search strategy**

#1 "random\*" or allocation or "random allocation" or placebo or single blind or  
double blind or "randomized controlled trial\*" or RCT or "clinical trial \*" or "case  
stud\*" or "qualitative stud\*"

#2 randomized controlled trial:pt or clinical trial:pt

#3 #1 or #2

#4 Chronic Airflow Obstruction:ti,ab,kw or Chronic Obstructive Airway  
Disease:ti,ab,kw or Chronic Obstructive Lung Disease:ti,ab,kw or Chronic  
Obstructive Pulmonary Disease:ti,ab,kw or COAD:ti,ab,kw or COPD:ti,ab,kw

#5 mindfulness:ti,ab,kw or mindfulness-based cognitive therapy:ti,ab,kw or  
MBCT:ti,ab,kw or mindfulness-based stress reduction:ti,ab,kw or MBSR:ti,ab,kw or  
meditation:ti,ab,kw or mindfulness meditation:ti,ab,kw or acceptance commitment  
therapy:ti,ab,kw or dialectical behavior therapy:ti,ab,kw or cognitive behavioral stress  
management:ti,ab,kw or integrative body–mind training:ti,ab,kw or

mindfulness-related interventions:ti,ab,kw or Vipassana:ti,ab,kw or Zen:ti,ab,kw or  
 mantra meditation:ti,ab,kw or 'compassion focused therapy:ti,ab,kw

#6 #3 and #4 and #5

### Web of science search strategy

#1 TS=("random \*" OR allocation OR "random allocation" OR placebo OR single  
 blind OR single blind method OR double blind OR double blind method OR  
 "randomized controlled trial\*" OR "randomized controlled trial\*" OR "RCT" OR  
 "clinical trial \*"OR "case stud\*" OR "qualitative stud\*")

#2 TS=( Chronic Airflow Obstruction OR Chronic Obstructive Airway Disease OR  
 Chronic Obstructive Lung Disease OR Chronic Obstructive Pulmonary Disease OR  
 COAD OR COPD )

#3 TS=( mindfulness OR mindfulness-based cognitive therapy OR MBCT OR  
 mindfulness-based stress reduction OR MBSR OR meditation OR mindfulness  
 meditation OR acceptance commitment therapy OR dialectical behavior therapy OR  
 cognitive behavioral stress management OR integrative body–mind training OR  
 mindfulness-related interventions OR Vipassana OR Zen OR mantra meditation OR  
 compassion focused therapy)

#4 #3 AND #2 AND #1

### CNKI search strategy

(SU = '随机' OR SU = '随机分配' OR SU = '随机对照' OR SU = '对照' OR SU = '盲法' OR SU = '单盲'  
 OR SU = '双盲' OR SU = '随机对照实验' OR SU = '随机对照研究' OR SU = 'RCT' OR SU = '临床试  
 验' OR SU = '临床研究' OR SU = '临床观察' OR SU = '临床试验' OR SU = '个案研究' OR SU = '质性  
 研究') AND ( SU = '慢性阻塞性肺炎' OR SU = '慢性阻塞性肺部疾病' OR SU = 'COPD' OR SU =  
 'COAD') AND ( SU = '正念' OR SU = '冥想' OR SU = '正念认知疗法' OR SU = ' MBCT' OR SU = '正  
 念减压疗法' OR SU = 'MBSR' OR SU = '正念冥想' OR SU = '接受与承诺疗法' OR SU = '辩证行为  
 疗法' OR SU = '认知行为压力管理' OR SU = '整合身心训练' OR SU = '内观' OR SU = '禅' OR SU =  
 '曼陀罗禅修' OR SU = 同情聚焦治疗)



**CINAHL search strategy**

S1 MH("Random Assignment" OR "Placebos" OR "Placebo Effect" OR "Single-Blind" OR "Double-Blind" OR "Randomized Controlled Trial\*" OR "Clinical Trial\*" OR "Case Stud\*" OR "qualitative stud\*")

S2 TX(random OR allocation OR "random allocation" OR placebo OR single blind OR double blind OR "random controlled trial\*" OR RCT OR "Clinical Trial\*" OR "Case stud\*" OR "qualitative stud\*" )

S3 S1 OR S2

S4 AB(Chronic Airflow Obstruction OR Chronic Obstructive Airway Disease OR Chronic Obstructive Lung Disease OR Chronic Obstructive Pulmonary Disease OR COAD OR COPD)

S5 AB(mindfulness OR mindfulness-based cognitive therapy OR MBCT OR mindfulness-based stress reduction OR MBSR OR meditation OR mindfulness meditation OR acceptance commitment therapy OR dialectical behavior therapy OR cognitive behavioral stress management OR integrative body–mind training OR mindfulness-related interventions OR Vipassana OR Zen OR mantra meditation OR compassion focused therapy)

S6 S3 AND S4 AND S5

**psychINFO search strategy**

1 ((doubl\* or singl\*) adj blind\*).mp.or ((random\* or clinical or control\*) adj (trial\* or study or studies)).mp.or ( clinical trial\* ).mp.or((case or qualitative) adj (study or studies)).mp.or( case stud\*).mp.or (qualitative stud\*).mp.

2 (Chronic Airflow Obstruction).mp.or(Chronic Obstructive Airway Disease).mp.or (Chronic Obstructive Lung Disease).mp.or(Chronic Obstructive Pulmonary Disease).mp.or (COAD ).mp.or(COPD).mp.

3 (mindfulness).mp.or(mindfulness-based cognitive therapy).mp.or (MBCT).mp.or(mindfulness-based stress reduction).mp.or (MBSR ).mp.or(meditation).mp.or (mindfulness meditation).mp.or(acceptance

1  
2  
3  
4 commitment therapy).mp.or (dialectical behavior therapy).mp.or(cognitive behavioral  
5 stress management).mp.or (integrative body–mind  
6 training ).mp.or(mindfulness-related interventions ).mp.or  
7 (Vipassana).mp.or(Zen).mp.or (mantra meditation ).mp.or(compassion focused  
8 therapy).mp.  
9

10  
11  
12  
13 4 1 and 2 and 3  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 checklist: recommended items to address in a systematic review protocol\***

Section and topic	Item No	Checklist item	Reported on page#
<b>ADMINISTRATIVE INFORMATION</b>			
Title:			
Identification	1a	Identify the report as a protocol of a systematic review	1
Update	1b	If the protocol is for an update of a previous systematic review, identify as such	
Registration	2	If registered, provide the name of the registry (such as PROSPERO) and registration number	2
Authors:			
Contact	3a	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author	1
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review	10
Amendments	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	N/A
Support:			
Sources	5a	Indicate sources of financial or other support for the review	10
Sponsor	5b	Provide name for the review funder and/or sponsor	10
Role of sponsor or funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol	10
<b>INTRODUCTION</b>			
Rationale	6	Describe the rationale for the review in the context of what is already known	3-6
Objectives	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	3-6
<b>METHODS</b>			

Eligibility criteria	8	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review	6-7
Information sources	9	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage	6-8
Search strategy	10	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated	16-21
Study records:			
Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review	8-9
Selection process	11b	State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)	8-9
Data collection process	11c	Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators	8
Data items	12	List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications	7
Outcomes and prioritization	13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale	7
Risk of bias in individual studies	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis	8
Data synthesis	15a	Describe criteria under which study data will be quantitatively synthesised	8-9
	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as $I^2$ , Kendall's $\tau$ )	8-9
	15c	Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression)	9
	15d	If quantitative synthesis is not appropriate, describe the type of summary planned	N/A

Meta-bias(es)	16	Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies)	9
Confidence in cumulative evidence	17	Describe how the strength of the body of evidence will be assessed (such as GRADE)	N/A

**\* It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0.**

*From: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015 Jan 2;349(jan02 1):g7647.*